

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 26, 2005, 12:54:26 ; Search time 191 seconds
 (without alignments)
 777.208 Million cell updates/sec

Title: US-10-019-337E-9
 Perfect score: 1413
 Sequence: 1 MLLGAYLRLVNERPGQAVW.....SVLQDQWMNPYQNAGQAKVEA 258

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqB, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0
 Maximum DB seq length: 200000000

Post-processing: Minimum Match 0‡
 Maximum Match 100‡
 Listing first 45 summaries

Database : UniProt 02:*

1: uniprot_sprot:
 2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1386	98.1	273	1 GFR4_RAT
2	1075.5	76.1	260	1 GFR4_MOUSE
3	767.5	54.3	299	1 GFR4_HUMAN
4	585.5	41.4	431	1 GFR4_CHICK
5	476.5	33.7	481	2 Q8RTW8
6	476.5	33.7	481	2 Q8T1Z1
7	471	33.3	330	2 Q9ZK2
8	469	33.2	358	2 Q9ZK3
9	469	33.2	444	2 Q79X9
10	469	33.2	464	2 Q35977
11	465	32.9	463	1 GFR2_MOUSE
12	465	32.9	463	2 Q920Y3
13	465	32.9	465	1 GFR1_HUMAN
14	464	32.8	331	2 Q725C2
15	464	32.8	463	2 Q725C2
16	464	32.8	468	1 GFR1_MOUSE
17	464	32.8	468	2 Q35246
18	463	32.8	1 GPR1_CHICK	
19	462	32.7	463	2 Q35748
20	462	32.7	464	1 GFR2_HUMAN
21	462	32.7	464	1 AAH41688
22	462	32.7	468	1 GFR1_RAT
23	460.5	32.6	465	1 GFR2_CHICK
24	459	32.5	472	2 Q9BT9
25	459	32.5	472	2 AKI1260
26	454.5	30.8	495	2 Q6TC3
27	366.5	25.9	397	2 AAH66202
28	364.5	25.8	385	2 Q9R2D
29	364.5	25.8	397	2 GPR3_MOUSE
30	354.5	25.8	397	2 Q9QZG2
31	354.5	25.7	397	2 Q9QZG2

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

ALIGNMENTS

RESULT 1	
ID	GFR4_RAT
AC	Q9EP12; Q9EP13;
DT	10-OCT-2003 (Rel. 42, Created) 10-OCT-2003 (Rel. 42, Last sequence update)
DE	GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)
DB	(Persephin receptor).
GN	Name=Gfr4; Name=Gfr4; Name=Gfr4;
OS	Rattus norvegicus (Rat).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
RA	Mammalia; Butheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
RA	SCOTT R., Van Gompel P., Iesage A.S.J., Verhaestelt P., Ibanez C.F., Gordon R.D.,
RA	"Mammalian GFRalpha-4, a divergent member of the GFRalpha family of coreceptors for Glial cell line-derived neurotrophic factor ligands, is a receptor for the neurotrophic factor persephin." J. Biol. Chem. 275:39427-39434 (2000).
RL	-I- FUNCTION: Receptor for persephin. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor. May be important in C-cell development and, in the postnatal development of the adrenal medulla.
CC	-I- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (isoform A). Secreted (isoform B) (potential).
CC	-I- ALTERNATIVE PRODUCTS:
CC	Event=Alternative splicing; Named isoforms=2; Comment=Additional isoforms seem to exist;
CC	Name=A';
CC	Name=B';
CC	Isoform-Q9EP12-1; Sequence=Displayed;
CC	Isoform-Q9EP12-2; Sequence=VSP_007230;
CC	-I- TISSUE SPECIFICITY: Weakly expressed in heart, brain and testis.
CC	-I- SIMILARITY: Belongs to the GDNFR family.
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isp-sib.ch).
CC	EMBL; EMBL; AU294475; CAC16420.1; -;
DR	EMBL; AU294476; CAC16421.1; -;
DR	RGD; G20503; Gfr4.
DR	InterPro; IPR005438; GDNF_receptor.
PFam; PF02351; GDNF; 1.	Q9QZG2 anopheles gambiae
Q9QZG2	Q9QZG2 rat mus musculus

DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 KW Polymorphism; Receptor; Signal;
 FT SIGNAL 1 Potential;
 FT CHAIN ? GDNF family receptor alpha 4.
 FT PROPER 251 273 N-linked (GlcNAc. .) (Potential).
 FT CARBOHYD 192 192 Removed in mature form (Potential).
 FT LIPID 250 250 GPI-anchor amidated asparagine (Potential).
 FT VARSPLIC 253 273 CCFPLWVSSMSITIALQALL -> QAKVEA (in isoform b).
 FT VARIANT 257 257 /FTId=VSP_007230.
 FT SEQUENCE 273 AA; 29682 MW; E0B876AB2ACCEB04 CRC64;
 SQ W -> R (in 50% of the molecules).
 Query Match Similarity 98.1%; Score 1386; DB 1; Length 273;
 Best Local Similarity 100.0%; Pred. No. 1.2e-109;
 Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MLSGAVLVRVNNERPGOAVLNSLGCGSASSTEGNRCVERAETADOCQQLSERVYAQ 60
 Db 1 MLSGAVLVRVNNERPGOAVLNSLGCGSASSTEGNRCVERAETADOCQQLSERVYAQ 60
 Qy 61 CLGRAGWRGIGSCVSRSRCAARLRRPAREPAPALTHALLFGCGCPRACERRRTPACA 120
 Db 61 CLGRAGWRGIGSCVSRSRCAARLRRPAREPAPALTHALLFGCGCPRACERRRTPACA 120
 Qy 121 FSGPOLAPPSCLKPIDRCRERSRERRPRLAFQASCAPARGPDCGCPERGGPROCLRAYGL 180
 Db 121 FSGPOLAPPSCLKPIDRCRERSRERRPRLAFQASCAPARGPDCGCPERGGPROCLRAYGL 180
 Qy 181 VGTUVTPNVDLNSARVAPWCGEASGNRREECAFRLKTRNPCLDGA1QADFSSPSV 240
 Db 181 VGTUVTPNVDLNSARVAPWCGEASGNRREECAFRLKTRNPCLDGA1QADFSSPSV 240
 Qy 241 LDQDNPKYQAG 252
 Db 241 LDQDNPKYQAG 252
 CC IsoId=Q9JUJT2-1; Sequence=Displayed;
 CC IsoId=Q9JUJT2-2; Sequence=VSP_007227;
 CC IsoId=Q9JUJT2-3; Sequence=VSP_007228; VSP_007229;
 CC IsoId=Q9JUJT2-4; Sequence=VSP_007226;
 CC IsoId=Q9JUJT2-5; Sequence=VSP_007226; VSP_007227;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Name=b3;
 CC IsoId=Q9JUJT2-6; Sequence=VSP_007226; VSP_007228; VSP_007229;
 CC Note=Alternative N-terminal. Probably non-functional;
 -!- TISSUE SPECIFICITY: Expressed in many tissues including adrenal
 CC medulla, brain neurons, with highest levels in the cerebral
 CC cortex and hippocampus. Moderate levels found in the gut circular
 CC muscle and myenteric ganglia as well as in other peripheral
 CC ganglia, including the sensory dorsal root and trigeminal as well
 CC as superior cervical and sympathetic chain ganglia. Isoform a1,
 CC isoform a2, isoform b1 and isoform b2 are exclusively found in the
 CC thyroid, parathyroid and pituitary glands.
 CC -!- DEVELOPMENTAL STAGE: Expressed in several tissues at different
 CC embryonic and postnatal stages such as the condensing mesenchyme
 CC of developing bones and developing nervous system. Expressed in
 CC the developing pituitary gland from E16 and in developing thyroid
 CC C-cells from E14. In the ventral spinal cord, levels decline
 CC before birth. In the parathyroid, levels first detected in 3-to 6-
 CC week-old mice with high expression. In the adrenal medulla,
 CC expressed only in newborn, postnatal (P08) and adult mice. Isoform
 CC a1 and isoform b1 are preferentially expressed in 3-week-old
 CC thyroid, isoform a2 and isoform b2 in newborn and 6-week-old
 CC thyroid glands as well as in postnatal adrenal and pituitary
 CC glands.
 CC -!- SIMILARITY: Belongs to the GDNFR family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 DR EMBL; AU276870; CAB9690.1; --
 DR EMBL; AU276871; CAB89691.1; --
 DR EMBL; AU276872; CAB89692.1; --
 DR EMBL; AU276514; CAB9697.1; --
 DR EMBL; AU276515; CAB89688.1; --
 DR EMBL; AU276516; CAB89689.1; --
 DR MGD; MGI:1341873; Gfrα4.
 DR InterPro; IPR00338; GDNF receptor.
 DR PIR; PIR02351; GDNF; 1.
 DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 KW Receptor; Signal;
 FT SIGNAL 1 Potential;
 FT CHAIN 24 237 GDNF family receptor alpha 4.
 FT PROPER 238 260 Removed in mature form (Potential).
 FT CARBOHYD 184 184 N-linked (GlcNAc. .) (Potential).
 FT LIPID 237 237 GPI-anchor amidated threonine (Potential).
 FT VARSPLIC 1 17 GSQRGS (in isoform b1, isoform b2 and
 Isoform b3).
 FT VARSPLIC 245 260 USMLYLTLQALL -> ARHEWPEKSIKQOKSLFCPEA
 CC QGVFLAVCHTHFGSPEPALIIRRMMNRGRHS (in isoform
 CC a2 and isoform b2).
 CC /FTId=VSP_007227.
 CC Comment=additional isoforms seem to exist. Tissue-specific and,
 CC developmentally regulated splicing;
 CC Name=b1;

FT	a3 and isoform b3).
FT	/Frid=vsp 007228.
FT	Misseq (In isoform a3 and isoform b3).
FT	/Frid=vsp 007229.
SQ	Query Match 76.1%; Score 1075.5; DB 1; Length 260;
	Best Local Similarity 89.6%; Pred. No. 2.6e-83;
	Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;
Qy	27 GSASSTEGNRVERAECTADEPQCQLSEYVVAQCLSLR--GWRGROSCLVSRCLR 83
Db	16 GSASFTDINRKCVPAEACTADEDCQQLSSEYVACLGPRGPCCVSRCLR 75
Oy	84 RFARGPPALTHALLFCCEGPGCAERQRQTAPACAFSGPQLAPPCLKPLDRCSRR 143
Db	76 RFPIRGPPALTHALLFCCEGPGCAERQRQTAPACAFSGPQLAPPCLKPLDRCSRL 135
Oy	144 CRPLLFQASCAPAGSRRCEBEGGRGRCLRYAGLTVTIPNLYLDNSARVAPMGC 203
Db	136 CRRPLLAQASCAPAGSRRCEBEGGRGRCLRYAGLTVTIPNLYLDNSARVAPMGC 195
Oy	204 EAASNRRBECAFRLKFTNPCHDGTAFPSQSOPVHQD 244
Db	196 AASGNRRBECAFRLKFTNPCHDGTAFPSQSOPVHQD 236
RESULT 3	
GFR4_HUMAN	STANDARD; PRT; 299 AA.
AC	Q9GZ7; Q9HJ91; Q9H192; 10-OCT-2003 (Rel. 42, Created)
DT	10-OCT-2003 (Rel. 42, Last sequence update)
DT	05-JUL-2004 (Rel. 44, Last annotation update)
DE	GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)
DB	(Persephin receptor).
GN	Name=GFR4;
OS	Homo sapiens (Human).
OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX	NCBI_Taxid=9606;
RN	SEQUENCE FROM N.A. (ISOFORMS GFRALPHA4A; GFRALPHA4B AND GFRALPHA4C), AND GPI-ANCHOR.
RC	TISSUE=Thyroid;
RX	MEDLINE=21153758; PubMed=11116144; DOI=10.1074/jbc.M008219200;
RA	Lindahl M., Poteryaev D., Yu L., Arumua U., Timusk T., Bongerzone I., Aiello A., Pierotti M.A., Airaksinen M.S., Saarma M.;
RA	"Human glial cell line-derived neurotrophic factor receptor alpha4 is the receptor for peripherin and is predominantly expressed in normal and malignant thyroid medullary cells.";
RL	J. Biol. Chem. 276:9344-9351(2001).
[2]	SEQUENCE FROM N.A. (ISOFORM GFRALPHA4A).
RA	Zhou B., Levinson B., Gitschier J.; Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
[3]	SEQUENCE FROM N.A. MEDLINE=21153749; PubMed=11780052; DOI=10.1038/414065a;
RP	SEQUENCE FROM N.A. MEDLINE=21153749; PubMed=11780052; DOI=10.1038/414065a;
RA	Deloutas P., Matthews L.H., Aburat J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagley C.L., Bailey J., Barlow K.N., Beard L.M., Beare D.M., Beasley O.P., Bird C.P., Blahey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., Butler A.P., Gardner C., Carter N.P., Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., Coulon A., Corrill G.J., Deachman R., Dhani P.D., Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., Huckle B., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., Kay M.P., Kimberley A.M., Knights A., Laird G.K., Lawlor S., Lehaeala M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA
RA	Marsh V.L., Martin S.L., McConnaughey L.J., McLay K., McMurray A.A., Milne S.A., Mistry D., Moore M.J.P., Mullikin J.C., Nickerson T., Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., Philimore J.C.T., Pratlein D., Pratlein S.R., Plumb R.W., Ramsey H., Rice C.M., Ross M.T., Scott C.E., Shhra H.K., Showkeen R., Sims S., Shue C.D., Smith M.L., Soderlund C., Steward J.B., Sulston J.E., Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M., Williams S.A., Whitehead S.L., Whitaker P., Willey D.L., Williams L., Williams S.A., Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; "The DNA sequence and comparative analysis of human chromosome 20.", Nature 414:865-871(2001).
RA	CC -I- FUNCTION: Receptor for persephin. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor. May be important in C-cell development and, in the postnatal development of the adrenal medulla.
CC	-I- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (isoforms GFRalpha4a and GFRalpha4b). Secreted (isoform GFRalpha4c).
CC	-I- ALTERNATIVE PRODUCTS: Event=Alternative splicing; Named isoforms=3; Comment="Additional isoforms seem to exist;"
CC	Name=GFRalpha4b; IsoId=Q9GZ7-1; Sequence=Displayed;
CC	Iba-D-Q9GZ7-2; Sequence=vsp_007223;
CC	-I- TISSUE SPECIFICITY: Predominantly expressed in the adult thyroid gland. Low levels also found in fetal adrenal and thyroid glands.
CC	-I- SIMILARITY: Belongs to the GDNFR family.
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.ebi-sib.ch/announce/ or send an email to license@ebi-sib.ch).
CC	DR EMBL; AJ291573; CAC19690.1; DR EMBL; AU291674; CAC19691.1; DR EMBL; AJ291675; CAC19692.1; DR EMBL; AF253118; AAC26925.1; DR EMBL; AL356755; CAC16508.2; DR Genew; HGNC:13821; GFR4; InterPro; IPR00438; GDNF_receptor; DR InterPro; IPR00438; GDNF_receptor; PRAM; PF0231; GDNF; I. DR PRINTS; PR01316; GDNFRECEPTOR.
KW	Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.
FT	SIGNAL 1 20 Potential.
FT	CHAIN 21 278 GDNF family receptor alpha 4.
FT	PROPEP 279 299 Removed in mature form (Potential).
FT	CARBHYD 208 208 N-linked (GlcNAc . .) (Potential).
FT	LIPID 278 278 GPI-anchor amidated glycine (Potential).
FT	VARSPLIC 132 197 CARAAAKFWGRGNGLFAHRPPAQSPPGSLVPSAQ RPRRLPGPGPARQGPRGVPA -> PRLLAQFSCTP APSAQCLIDQGRCRRAYSLV (In isoform GFRalpha4a)
FT	/Frid=vsp 007224.
FT	CARAACQFWGRGNGLFAHRPPAQSPPGSLVPSAQ /Frid=vsp 007223.
FT	CARAAACQFWGRGNGLFAHRPPAQSPPGSLVPSAQ /Frid=vsp 007225.
SQ	SEQUENCE 299 AA; 31669 MW; 844388342FF10801 CRC64;
	Query Match 54.3%; Score 267.5; DB 1; Length 299;
	Best Local Similarity 62.5%; Pred. No. 4.3e-57;

Matches	157;	Conservative	10;	Mismatches	51;	Indels	33;	Gaps	3;
Qy	27	GSASSTGCRVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFF	86	CC	CC	CC	CC	CC	CC
Db	16	GSASSVGGRNRYCTDAACTAACRQRSLSERVAQCLGRA--AQGCCPRARCREARRFF	72	DR	DR	DR	DR	DR	DR
Qy	87	ARGPPALTHAILFCGGEGPACAAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCR-	145	DR	Inter-Pro; IPR003438; GDNF-receptor.	pfam; PF02351; GDNF; I.	PRINTS; PRO1316; GDNFRECEPTOR.	PRINTS; PRO1316; GDNFRECEPTOR.	PRINTS; PRO1316; GDNFRECEPTOR.
Db	73	ARGPPALTHAILFCGGEGPACAAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCR-	132	DR	DR	DR	DR	DR	DR
Qy	146	-----PFLAFAGASCAPARGRDGEPEEGRCRAY 177	FT	KW	SIGNAL	1	19	19	19
Db	133	ARAAGCPWGRGGRGLSPAHRRPAQASPPQELSGLVLHPSAQAPRRLPAGPGRPLPARLRGP	192	FT	CHAIN	20	403	403	403
Qy	178	AGL-VGTUVTNTYLDNSVARAPWGCEASGNRRECERKLTTRNLGIAQFSS 236	FT	PROTEIN	404	431	Removed in mature form	Potential.	Potential.
Db	193	RGVPGTAVIPTNVDSVARAPWCDGAGSNRRDCEARGLTFRNRLGDGAQFASG 252	FT	CARBONID	180	180	N-linked (GlcNAc. . .)	(Potential).	(Potential).
Qy	237	QPSVHQDWNP 247	FT	CARBONID	296	296	N-linked (GlcNAc. . .)	(Potential).	(Potential).
Db	253	WPPVLLDQNP 263	FT	CARBONID	308	308	N-linked (GlcNAc. . .)	(Potential).	(Potential).
RESULT 4									
GFR4-CHICK STANDARD; PRT; 431 AA.									
AC	093512;	10-OCT-2003 (Rel. 42, Created)	DT	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	Qy	32	Qy
DT	05-JUL-2004 (Rel. 44, last annotation update)	DT	QY	140	TQVNRCDAAKACGNVDEMCORLIRYEVSKIRILLA-RADTNKSKKALRKPFDRVPP 197	Db	140	140	140
DE	GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4). Name=GFR4;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	Db	198	198	198
GN	Gallus gallus (Chicken)	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	Db	256	256	256
OS	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauaria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	Db	316	316	316
OC	NCI-TAXID=9031;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	SEQUENCE FROM N.A.	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	Db	140	140	140
RC	TISSUE-Embryonic brain;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	Db	198	198	198
RX	MEDLINE:98313402; PubMed=9647690;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	Db	256	256	256
RA	Thompson J., Doxakis E., Pinon L.G.P., Strachan P., Buj-Bello A., Watt S., Buchman V.L., Davies A.M.; GFRalpha-4, a new GDNF family receptor.; Cell. Neurosci. 11:117-126(1998).	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	Db	316	316	316
RA	RA	RA	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
RA	RA	RA	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	Db	140	140	140
RA	RA	RA	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	Db	198	198	198
RA	RA	RA	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	Db	256	256	256
RA	RA	RA	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	Db	316	316	316
RA	RA	RA	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
RESULT 5									
Q98TM8 PRELIMINARY; PRT; 481 AA.									
AC	Q98TM8;	01-JUN-2001 (TREMBLrel. 17, Created)	DT	QY	98TM8	Q98TM8	Q98TM8	Q98TM8	Q98TM8
DT	01-JUN-2001 (TREMBLrel. 17, Last sequence update)	DT	QY	140	TQVNRCDAAKACGNVDEMCORLIRYEVSKIRILLA-RADTNKSKKALRKPFDRVPP 197	DB	140	140	140
DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)	DT	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
DE	GDNF family receptor alpha-1b. Name=gfralphab;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
GN	Brachydanio rerio (Zebrafish) (Danio rerio).	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OS	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	NCI-TAXID=1955;	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	SEQUENCE FROM N.A.	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	NCBI_TAXID=1955;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	SEQUENCE FROM N.A.	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	NCBI_TAXID=1955;	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	SEQUENCE FROM N.A.	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	PubMed:1466438; GO:000872; DR:InterPro; IPR003438; DR:Prints; PRO1316; GDNFRECEPTOR.	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	NCBI_TAXID=1955;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	SEQUENCE FROM N.A.	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	NCBI_TAXID=1955;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	SEQUENCE FROM N.A.	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	NCBI_TAXID=1955;	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	SEQUENCE FROM N.A.	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	NCBI_TAXID=1955;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	SEQUENCE FROM N.A.	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	NCBI_TAXID=1955;	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	SEQUENCE FROM N.A.	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	NCBI_TAXID=1955;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	SEQUENCE FROM N.A.	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	NCBI_TAXID=1955;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	SEQUENCE FROM N.A.	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	NCBI_TAXID=1955;	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	SEQUENCE FROM N.A.	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	NCBI_TAXID=1955;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	SEQUENCE FROM N.A.	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	NCBI_TAXID=1955;	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	SEQUENCE FROM N.A.	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	32	TEGNRCVTEAECTAEDQCOILSERVVAQCLGRAGWRGPSCVRSRCAIRRFFPFP 91	DB	140	140	140
OC	Shepherd I.T., Beattie C.E., Raible D.W.; Functional analysis of zebrafish GDNF.; Dev. Biol. 231:400-415(2001).	DB	QY	92	ALTHALIFCGCGEGRCAERRRQTFAFAPACAFSGPQLAPPSCIKPLDRCSRRCRPRLPAP 151	DB	198	198	198
OC	NCBI_TAXID=1955;	DB	QY	152	QASCAPASPSRDGCSEEGRCRAYAAGLVGTUTPNLNDNSVARAPWGCEASGNRE 211	DB	256	256	256
OC	SEQUENCE FROM N.A.	DB	QY	212	ECARKLKEFRNPLDGAQFD-----SSAPSV-LQDQNPYQYQAGQA 254	DB	316	316	316
OC	MEDLINE:21135398; PubMed=11237470;	DB	QY	316	ECESFHLFLTDIVNCLQNAQAFNGTYINAATAPSISITQMYQERNANRA 367	Qy	32	32	32</

SQ	SEQUENCE	PRT	AA:	MW:	CRC64;
Query Match	33.7%; Score 476.5; DB 2; Length 481;				
Best Local Similarity	39.9%; Pred. No. 3.6e-32;				
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;				
OY	27 GSASSTEGNRCTEAAEACTADEOCQQLRSEYYAQCLGRAGWGPSCVRSRRALRRP 86	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	152 GEAFTKDNCKNAAKACNLNTCKKRSLYISPTSRVS--TTEVNKRKRKHKALQFF 209	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	144 CIPRLFARQASCAPAPSGSRDGCBEGRGCRIVAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A2	PRELIMINARY;	PRT;	330 AA.
RESULT 6					
AAK1261					
ID	AAK1261 PRELIMINARY; PRT; 481 AA.	0922A2	PRELIMINARY;	PRT;	330 AA.
AC	AAK1261;	0922A2	PRELIMINARY;	PRT;	330 AA.
DT	02-MAR-2004 (TREMBLrel. 27, Created)	0922A2	PRELIMINARY;	PRT;	330 AA.
DT	02-MAR-2004 (TREMBLrel. 27, Last sequence update)	0922A2	PRELIMINARY;	PRT;	330 AA.
DE	GDNF family receptor alpha-1b.	0922A2	PRELIMINARY;	PRT;	330 AA.
GN	GFRALPHA1B.	0922A2	PRELIMINARY;	PRT;	330 AA.
OS	Brachydanio rerio (Zebrafish) (Danio rerio).	0922A2	PRELIMINARY;	PRT;	330 AA.
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.	0922A2	PRELIMINARY;	PRT;	330 AA.
OX	NCBI_TaxID:7955;	0922A2	PRELIMINARY;	PRT;	330 AA.
RN	[1]	0922A2	PRELIMINARY;	PRT;	330 AA.
RP	SEQUENCE FROM N.A.	0922A2	PRELIMINARY;	PRT;	330 AA.
RX	MEDLINE:21135398; PubMed:11237470;	0922A2	PRELIMINARY;	PRT;	330 AA.
RA	Shepherd J.T., Beattie C.E., Raible D.W.; Dev. Biol. 231:420-435(2001).	0922A2	PRELIMINARY;	PRT;	330 AA.
RT	"Functional analysis of zebrafish GDNF."	0922A2	PRELIMINARY;	PRT;	330 AA.
RL	[2]	0922A2	PRELIMINARY;	PRT;	330 AA.
RN	SEQUENCE FROM N.A.	0922A2	PRELIMINARY;	PRT;	330 AA.
RP	PubMed-14680438;	0922A2	PRELIMINARY;	PRT;	330 AA.
RX	PubMed-131_241-249(2004); Development. 131:241-249(2004); EMBL: AA436321; AAK1261.2; -.	0922A2	PRELIMINARY;	PRT;	330 AA.
RT	"Roles for GFRalpha1 receptors in zebrafish enteric nervous system development."	0922A2	PRELIMINARY;	PRT;	330 AA.
RL	EMBL: AA436321; AAK1261.2; -.	0922A2	PRELIMINARY;	PRT;	330 AA.
KW	Receptor.	0922A2	PRELIMINARY;	PRT;	330 AA.
SQ	SEQUENCE 481 AA; 53639 MW; 478917653049CB23 CRC64;	0922A2	PRELIMINARY;	PRT;	330 AA.
RESULT 7					
OY	22 LGCORGGSASSTEGNRCTEAAEACTADEOCQQLRSEYYAQCLGRAGWGPSCVRSRRRA 81	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	13 LSGCADPVSAESNHCDAAKACNLNDCKKLRSVVISICREIS--PTERGNRKRKHA 70	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	82 LRGFFAAGPPLTHALIFFCGCGBGPACERRROTAPACAFSGPQLAPPSCIKPLDRERS 141	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	71 LKOFFDPDRUSETYRMILFCSCDQACKERRORTILPSCSYDEKE--KPNCLDLRSLRD 128	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	142 RCRPRFAFQASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLND--VSARAV 199	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	129 HLCRSRLADFHANCRAKYRTTSCPANDYAOGLGSYAGMTCRDMDTNTYVDNSNPTGTWSP 188	0922A2	PRELIMINARY;	PRT;	330 AA.
OY	200 WGCEASGNRREBCEAFRKLFTRNCPCIDGATQAF 233	0922A2	PRELIMINARY;	PRT;	330 AA.
Db	189 WCNCRGGNMNBECBKELDFTENPCDRNAIQAP 222	0922A2	PRELIMINARY;	PRT;	330 AA.
RESULT 8					
O922A3					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	27 GSASSTEGNRCTEAAEACTADEOCQQLRSEYYAQCLGRAGWGPSCVRSRRALRRP 86	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	152 GEAFTKDNCKNAAKACNLNTCKKRSLYISPTSRVS--TTEVNKRKRKHKALQFF 209	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 9					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 10					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 11					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 12					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 13					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 14					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 15					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 16					
OY					
Query Match	33.7%; Score 476.5; DB 2; Length 481;	0922A3	PRELIMINARY;	PRT;	358 AA.
Best Local Similarity	39.9%; Pred. No. 3.6e-32;	0922A3	PRELIMINARY;	PRT;	358 AA.
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	87 ARGPPALTHALIFFCGC--EGPACABERROTAPACAPSGPQLAPPSCIKPLDRERSRR 143	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	210 DKUPPKHYSYGMFLFCSCPDSGHSACSERRQTTVPACSYEDKE--KPNCLSIQASCNHYI 267	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	144 CRPLRFAFOASCAPAPSGSRDGCPEGGPRCLRAYGLVGTWTPTYLNDNSVARAVPGC 203	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	268 CRSRLADFLTNCOPEARSISGCLKENYADCLLAYSGLIGTWTPTYLARPISVSPWDC 327	0922A3	PRELIMINARY;	PRT;	358 AA.
OY	204 EASGNRREBCEAFRKLFTRNCPCIDGATQAFDSS-----QPSVLODQWNPY 248	0922A3	PRELIMINARY;	PRT;	358 AA.
Db	328 SNSNGNKAECDKTEFFTNPNCRNAIQAFNGTDVGWMQPQPPIMSTPAPY 380	0922A3	PRELIMINARY;	PRT;	358 AA.
RESULT 17					
OY					
Query Match	33.7%; Score 476.5; DB 2				

DR MGD; MGI:1195462; Gfrα2.
 DR GO: GO:0004872; F-receptor activity; IEA.
 DR InterPro; IPR03438; GDNF_receptor.
 DR InterPro; IPR03504; GDNF_receptorA2.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PR01318; GDNFRALPHA2.
 DR Receptor; PR01316; GDNFRECEPTOR.
 SQ SEQUENCE 358 AA; 39700 MW; F440CB3B1F629225 CRC64;
 Query Match Similarity 33.2%; Score 469; DB 2; Length 358;
 Best Local Similarity 43.4%; Pred. No. 1. 2e-31; Indels 6; Gaps 3;
 Matches 89; Conservative 31; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNRCVVEAAEACTADQOCQOLSERVEYAQCLOGRAGWRGGSCVRSKRRAARRFFARGP 90
 Db 50 SAESNNHCLDAKACNLNNDCKKLRSYISICNREIS--PTERCNRKCHKALRQFDFR 107

QY 91 PALTHALIFGCCGCPACAAERRRQTAPACAFSGPQLAPPSCIKPLDRCRSRRCRPL 150
 Db 108 SEVTYMLFCSCQDQAACHERRQQTILSSEYDEKE--KPNCLDLRSLCRTHLICRSRLAD 165

QY 151 FQASCAPAPGSRDGCGPEREGGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEASGN 208
 Db 166 FHANCASRYRTITSQADNYQACIGSYAGMIGDMTPNIVDSNPTGIVVSPNCRGSGN 225

QY 209 RRRECECAFRKLFTRNPCLDGATOAFAF 233

Db 226 MESECEKKFLDKTFENPCLNIAQAF 250

RESULT 9
 Q792X9 PRELIMINARY; PRT; 444 AA.
 ID Q792X9 PRELIMINARY; PRT; 444 AA.
 AC DT 05-JUL-2004 (TREMBLrel. 27, Created)
 DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
 DE GDNF receptor-beta (Fragment).
 OS Rattus norvegicus (Rat).
 OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi; OX NCBI_TaxID=10116;
 RN RP SEQUENCE FROM N.A.
 RX MEDLINE-#8271460; PubMed=9608533;
 RA Trupp M., Raynoschek C., Belluardo N., Ibanez C.F.;
 RT "Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret Receptor tyrosine kinase.";
 RL Mol. Cell. Neurosci. 11:47-63 (1998).
 RN RP SEQUENCE FROM N.A.
 RC TISSUE=Hippocampus;
 RX MEDLINE=97322356; PubMed=9177201;
 RA Sanicola M., Hession C.A., Worley D.S., Carmillo P., Ehrenfels C.,
 RA Walus L., Robinson S., Jaworski G., Wei H., Tizard R., Whitty A.,
 RA Pepinsky R.B., Date R.L.;
 RT "Gliaal cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins";
 RL Proc. Natl. Acad. Sci. U.S.A. 94:6238-6243 (1997).
 DR EMBL; U07143; AAC5301.1; -.
 DR EMBL; U005226; BAB62247.1; -.
 DR InterPro; IPR03438; F-receptor activity; IEA.
 DR InterPro; IPR03504; GDNF_receptorA2.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PR01318; GDNFRALPHA2.
 DR PRINTS; PR01316; GDNFRECEPTOR.
 KW Receptor.
 PT NON_TER 444 AA; 49578 MW; A548644EDB36DF3 CRC64;
 SQ SEQUENCE 444 AA; 51668 MW; 81168301BS50D6CC CRC64;
 Query Match Similarity 33.2%; Score 469; DB 2; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1. 5e-31; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSTEGNRCVVEAAEACTADQOCQOLSERVEYAQCLOGRAGWRGGSCVRSKRRAARRFFAR 88
 Db 153 AVSTKSNHCLDAKACNLNNDCKKLRSYISICNREIS--PTERCNRKCHKALRQFDFR 210

QY 29 ASSTEGNRCVVEAAEACTADQOCQOLSERVEYAQCLOGRAGWRGGSCVRSKRRAARRFFAR 88
 Db 211 VSEVTYMLFCSCQDQAACHERRQQTILSSEYDEKE--KPNCLDLRSLCRTHLICRSRL 268

QY 89 GPPALTHALIFGCCGCPACAAERRRQTAPACAFSGPQLAPPSCIKPLDRCRSRRCRPL 148
 Db 89 GPALTHALIFGCCGCPACAAERRRQTAPACAFSGPQLAPPSCIKPLDRCRSRRCRPL 148

QY 149 FAQASCAPAPGSRDGCGPEREGGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEAS 206
 Db 269 ADFHANCASRYRTITSQADNYQACIGSYAGMIGDMTPNIVDSNPTGIVVSPNCRGSG 328

QY 207 GRRRECECAFRKLFTRNPCLDGATOAFAF 233
 Db 329 GMEEBECFKERDFTFENPCLNIAQAF 355

RESULT 10
 QY 89 GPPALTHALIFGCCGCPACAAERRRQTAPACAFSGPQLAPPSCIKPLDRCRSRRCRPL 148
 Db 211 VPSEVTYMLFCSCQDQAACHERRQQTILSSEYDEKE--KPNCLDLRSLCRTHLICRSRL 268

QY 149 FAQASCAPAPGSRDGCGPEREGGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEAS 206
 Db 269 ADFHANCASRYRTITSQADNYQACIGSYAGMIGDMTPNIVDSNPTGIVVSPNCRGSG 328

QY	31	STGNCNRCTEAAEACTADSDQCDQSRVQAQCLGRAGWRGPSCVRSRRALRPFANGP	90
GFR2_MOUSE	00842;	SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).	
ID	00842;	SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).	
AC	00842;	SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).	
DT	01-NOV-1997	(Rel. 35, Created)	
DT	01-NOV-1997	(Rel. 35, Last sequence update)	
DT	05-JUL-2004	(Rel. 44, Last annotation update)	
DE	Milbrandt J., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr.	GDNF family receptor alpha 2 precursor (GFR-alpha 2) (Neurturin receptor alpha) (NTRN-alpha) (GFR-beta) (GDNFR-beta) (neurotrophic factor receptor 2) (GDNF receptor beta) (GDNFR-beta).	
DE	GN	Name=Gfrα2; Synonyms=Ganfrb, Trn2;	
OS	Mus musculus (Mouse)	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	
OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buteria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
NCBI_TaxId=10090;			
RN	[1]		
RP	RP	SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).	
RX	Medline=97325793; PubMed=9182803;	Medline=97325793; PubMed=9182803;	
RA	Balon R.H., Tansey M.G., Golden J.P., Creedon D.J., Heuckeroth R.O., Keck C.L., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr.	Medline=97325793; PubMed=9182803;	
RA	"Trn2", a novel receptor that mediates neurturin and GDNF signaling through Ret.;"	Medline=97325793; PubMed=9182803;	
RT	Neuron 18:793-802(1997).	Medline=97325793; PubMed=9182803;	
RT	-1- FUNCTION: Receptor for neurturin. Mediates the NRTN-induced auto phosphorylation and activation of the RET receptor. Also able to mediate GDNF signaling through the RET tyrosine kinase receptor.	Medline=97325793; PubMed=9182803;	
RT	-1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).	Medline=97325793; PubMed=9182803;	
RT	-1- ALTERNATIVE PRODUCTS:	Medline=97325793; PubMed=9182803;	
RT	Event: Alternative splicing; Named isoform=2;	Medline=97325793; PubMed=9182803;	
CC	Name=2; Synonyms=Long;	Name=2; Synonyms=Short;	
CC	IsoId=00842-2; Sequence=VSP_001662;	IsoId=00842-2; Sequence=VSP_001662;	
CC	-1- TISSUE SPECIFICITY: Neurons of the superior cervical and dorsal root ganglia, and adult brain and testis. Low level in the spleen and in the adrenal gland.	-1- TISSUE SPECIFICITY: Neurons of the superior cervical and dorsal root ganglia, and adult brain and testis. Low level in the spleen and in the adrenal gland.	
CC	-1- SIMILARITY: Belongs to the GDNFR family.	-1- SIMILARITY: Belongs to the GDNFR family.	
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch) announce or send an email to licensee@isp-sib.ch).	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch) announce or send an email to licensee@isp-sib.ch).	
CC	-----	-----	
DR	Pfam: PF02351; GDNF; 1.	Pfam: PF02351; GDNF; 1.	
DR	PRINTS; PRO1316; GDNFRECEPTOR.	PRINTS; PRO1316; GDNFRECEPTOR.	
DR	InterPro; IPR003438; GDNF receptor.	InterPro; IPR003438; GDNF receptor.	
DR	EMBL; AF002701; AAC03548..1; -.	EMBL; AF002701; AAC03548..1; -.	
DR	MGI; MGI:1195462; Gfrα2.	MGI; MGI:1195462; Gfrα2.	
DR	InterPro; IPR005504; GDNF receptorA2.	InterPro; IPR005504; GDNF receptorA2.	
DR	Prints; PR02351; GDNF; 1.	Prints; PR02351; GDNF; 1.	
DR	PRINTS; PRO1316; GDNFRECEPTOR.	PRINTS; PRO1316; GDNFRECEPTOR.	
KW	Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.	Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.	
FT	SIGNAL	21	Potential.
FT	CHAIN	22	GDNF family receptor alpha 2.
FT	PROPEP	444	Removed in mature form (Potential).
FT	CARBHYD	52	N-linked (GCNAc. .) (Potential).
FT	CARBHYD	357	N-linked (GCNAc. .) (Potential).
FT	LIPID	413	N-linked (GCNAc. .) (Potential).
FT	VARSPLIC	443	GPI-anchor amidated Serine (Potential).
FT		146	Missing (in isoform 2).
SO	SEQUENCE	463 AA;	51598 MW;
SO	SEQUENCE	463 AA;	51598 MW;
Query Match	32.9%	Score 465; DB 2; Length 463;	
Best Local Similarity	42.9%	Pred. No. 3 3e-31; Indels 6; Gaps 3;	
Matches	88;	Conservative 32; Mismatches 79; Indels 6; Gaps 3;	
QY	31	SETYRMFLFCGCGPACERRROTAPACAFSPQRQLAPPSCIKPLDRCRERSRCRPRIFP	90
Db	155	SAKSNHCLDAAKANLNDKCKRSVSYTICIREIS--PTECNRKCKAQRERPVF	212
QY	91	PAUTHALLFCGGEGPACERRROTAPACAFSPQRQLAPPSCIKPLDRCRERSRCRPRIFP	150
Db	213	SETYRMFLFCGCGPACERRROTAPACAFSPQRQLAPPSCIKPLDRCRERSRCRPRIFP	270
QY	151	FAASCAPAGPSDGGCPERGGPCLRAYLAGVYQWVWTNYLD--VSARVAPCGCAGSN	208

DR EMBL; AF058999; AAC1431.1; JOINED.
 DR EMBL; AF058990; AAC1431.1; JOINED.
 DR EMBL; AF058991; AAC1431.1; JOINED.
 DR EMBL; AF058992; AAC1431.1; JOINED.
 DR EMBL; AF058993; AAC1431.1; JOINED.
 DR EMBL; AF058994; AAC1431.1; JOINED.
 DR EMBL; AF058995; AAC1431.1; JOINED.
 DR EMBL; AF058996; AAC1431.1; JOINED.
 DR EMBL; AF058997; AAC1431.1; JOINED.
 DR EMBL; AF058998; AAC1431.1; JOINED.
 DR EMBL; U95847; AAC71811.1; -. .
 DR Genew; HGNC:4243; GFRAL.
 DR MIM; 601496; -. .
 DR GO; GO:0019898; C: extrinsic to membrane; NAS.
 DR GO; GO:0004872; F: receptor activity; NAS.
 DR GO; GO:007166; P: cell surface receptor linked signal transdu. . ; NAS.
 DR InterPro; IPR00438; GDNF_receptor.
 DR Frame; PF02351; GDNF; 1.
 DR PRINTS; PRO1316; GDNFCEPTOR.
 KW Polymorphism; Receptor; Signal.
 FT SIGNAL 1 24
 FT CHAIN 25 429
 FT PROPEP 430 465
 FT DOMAIN 362 369
 FT CARBOHD 347 347
 FT CARBOHD 406 406
 FT LIPID 429 429
 FT VARSPLIC 140 144
 FT VARIANT 85 85
 FT VARIANT 366 366
 FT VARIANT 371 371
 FT VARIANT 371 371
 FT CONFLICT 245 245
 FT SEQUENCE 358 465 AA; 51455 MW; 9145500646777BD CRC64;
 Query Match 32.9%; Score 465; DB 1; Length 465;
 Best Local Similarity 41.9%; Pred. No. 3 3e-31;
 Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;
 Ov 33 EGRCVCEAACTADEQCOQLSERYYVAQCLGRAGWRGPSCVSRCCRRLRRFFARGPPA 92
 Db 150 KGNKNCLDAKACMNLDDICKKKYNSAYITPTTSV--SNDVCKWKRKCHAKRQPFDPKPAK 206
 Qy 93 LTHALLFCGGCAGCAERRRQFPAPACFSGPQLAPPSCLLPKDRCRSRGRPRPLFAQ 152
 Db 207 HSYGLMLCSRDCACTERRRQTPVSYE--EREKPLNQDSCCKNYCIRSIAADF 264
 Qy 153 ASCAPAPGCSRQDGCPPEEGPRCIRAYAGLVLGVPTPNLDRNARVARAPWCGCEASGRREE 212
 Db 265 TNQCPESRSVSSLKENYIADCLLAYSGLIGTQMPNTYIDSSLVAPWCDCSNSGNDLEE 324
 Qy 213 CFAFKLKFTRICFLDGAQAFSSQPSVLIQDWNPN 247
 Db 325 CLKFLNPKDNTCLKNAIQAFNGNSDVTV--WQP 356
 RESULT 14
 Q7Z5C2 PRELIMINARY; PRT; 331 AA.
 ID Q7Z5C2
 AC Q7Z5C2;
 DT 01-OCT-2003 (TREMBrel. 25, Created)
 DT 01-OCT-2003 (TREMBrel. 25, Last sequence update)
 DT 01-MAR-2004 (TREMBrel. 26, Last annotation update)
 DE Glial cell line-derived neurotrophic factor family receptor
 DR alpha2C.

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; vertebrata; Buteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TAXID:9606;
 RN [1]
 RP SEQUENCE FROM N. A.
 RC STRAIN=C57;
 RX MEDLINE=98252741; PubMed=9592044;
 RA Dey B. K., Wong Y.W., Too H.P.;
 RT "Cloning of a novel murine isoform of the glial cell line-derived
 neurotrophic factor receptor.";
 RL NeuroReport 9:37-42 (1998);
 EMBL; AP01572; AAB86600.1; -. .
 DR MGD; MGI:1100842; GFRAL.
 DR GO; GO:0040872; F: receptor activity; IEA.
 DR Interpro; IPR00438; GDNF receptor.
 DR Interpro; IPR005503; GDNF_receptorAI.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Receptor.
 SQ SEQUENCE 331 AA; 36470 MW; 10ECFA5492E2393C CRC64;
 SQ SEQUENCE 331 AA; 36470 MW; 10ECFA5492E2393C CRC64;
 Query Match 32.8%; Score 464; DB 2; Length 331;
 Best Local Similarity 38.7%; Pred. No. 2 9e-31;
 Matches 92; Conservative 38; Mismatches 102; Indels 6; Gaps 3;
 Ov 22 IScORGASSTSGNCVTEAECTADQOCQQRSEVVAQCLGRAGWRGPSCVSRERRA 81
 Db 13 LGTGADPVVSAKSNCDAKACNCLNNKLURKSVISICRREIS--PTERCNRKHKA 70
 Ov 82 LRFFPAGPALLTHALFCGGCAGCERROTPAPACFSGPQLAPPSCLLPKDRERS 141
 Db 71 LAQPFDPDVSEYTYRMFCSDQACIERRQPTLSQSYKE--KPNCLDQVGRTD 128
 Ov 142 RRCRPRIFAFQASCAPAGPSRQDGCPERGGPRCIRAYAVLGLVGTWVTPNLDN--VSARVAP 199
 Db 129 HICRSRADFHANCRASXQYTIVSCPADNYQACLGSIKAMIGDMTENVWDSSTPGIVSP 188
 Ov 200 WGCCEASGNRERFCEARFKLFRNPICDGAQAFDQSSPSVUQDQWNPYQNGAQAKVE 257
 Db 189 WCGSRGSNNMEEBCEKFLDFTENPCILRNIAQFGNCDVNVS PKGSFOAQAPRVE 246

RESULT 15
 ID Q35252 PRELIMINARY; PRT; 463 AA.
 ID Q35252
 AC 035252;
 DT 01-JAN-1998 (TREMBrel. 05, Created)
 DT 01-JUN-2003 (TREMBrel. 24, Last sequence update)
 DB GDNF receptor beta.
 GN Name=sigal; Synonyms=GDNFR-beta;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;
 OX NCBI_TAXID:10090;
 RN [1]
 RP SEQUENCE FROM N. A.
 RC STRAIN=C57;
 RX MEDLINE=98252741; PubMed=9592044;
 RA Dey B. K., Wong Y.W., Too H.P.;
 RT "Cloning of a novel murine isoform of the glial cell line-derived
 neurotrophic factor receptor.";
 RL NeuroReport 9:37-42 (1998);
 EMBL; AP01572; AAB86600.1; -. .
 DR MGD; MGI:1100842; GFRAL.
 DR GO; GO:0040872; F: receptor activity; IEA.
 DR Interpro; IPR00438; GDNF receptor.
 DR Interpro; IPR005503; GDNF_receptorAI.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Receptor.
 SQ SEQUENCE 463 AA; 51134 MW; BAFA21522622C037 CRC64;

Query Match 32.8%; Score 464; DB 2; Length 463;
 Best Local Similarity 41.2%; Pred. No. 4e-31;
 Matches 89; Conservative 32; Mismatches 87; Indels 8; Gaps 3;

Ov 32 TEGNRCEAACTADEQCOQLSERYYVAQCLGRAGWRGPSCVSRCCRRLRRFFARGPP 91

Search completed: January 26, 2005, 13:15:40
Job time : 193 secs

PRIOR APPLICATION NUMBER: 08/747,842
 PRIOR FILING DATE: 1996-11-13
 PRIOR APPLICATION NUMBER: 60/006,619
 PRIOR FILING DATE: 1995-11-13
 PRIOR APPLICATION NUMBER: 60/015,767
 PRIOR FILING DATE: 1996-04-16
 PRIOR APPLICATION NUMBER: 60/021,965
 PRIOR FILING DATE: 1996-06-27
 PRIOR APPLICATION NUMBER: 60/020,638
 PRIOR FILING DATE: 1996-06-27
 PRIOR APPLICATION NUMBER: 60/020,639
 PRIOR FILING DATE: 1996-06-27
 NUMBER OF SEQ ID NOS: 11
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 11
 LENGTH: 445
 TYPE: PRT
 ORGANISM: Rattus sp.
 US-08-861-990-11

Query Match Score 469; DB 4; Length 445;
 Best Local Similarity 43.0%; Pred. No. 1.7e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCYEAEEACTADEOCQQLRSYEVAAQCIGRAGWRGRGSCVSRCAERLRFAR 88
 Db 153 AVSTKSNHCLDAAKACNLDNCKKLRSYISICNREIS--PTERCRNRKCHKALROFFDR 210
 Qy 89 GPPALTHALLFCGGCAGCACERRQTAPACAFSGPQLAPPSCIKPLDRERSRRCPRL 148
 Db 211 VPSETYTMFLFCSCQDQACERRQTILPSCSYEDKE--KPNCLDLRSCTDHLCRSRL 268
 Qy 149 FAFOASCAPAPGSRDGCPEGGERPLRAYAGLVGTWTPNLYDN--VSARVAPWGCEAS 206
 Db 269 ADFHANCRASRYTITSCHPADNYOIGSYAGMIGFRDMTPNVDNSNPPTGIVSPWCNGRS 328
 Qy 207 GNRBECFPLKFTRNCPLDGAIAF 233
 Db 329 GNMBEECEKPLRDTENPCLRNAIQAF 355

RESULT 3
 US-08-957-063-6
 Sequence 6, Application US/08957063
 Patent No. 6025157

GENERAL INFORMATION:
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
 TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/957,063
 FILING DATE: 19-Jun-2000
 CLASSIFICATION: <Unknown>
 APPLICATION NUMBER: 08/957,063

PRIOR APPLICATION DATA:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 913
 FILING DATE: 18-Feb-1997
 CLASSIFICATION: <Unknown>
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD, Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE DOCKET NUMBER: P1086P2

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 464 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear
 US-08-957-063-6

Query Match Score 469; DB 3; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCYEAEEACTADEOCQQLRSYEVAAQCIGRAGWRGRGSCVSRCAERLRFAR 88
 Db 153 AVSTKSNHCLDAAKACNLDNCKKLRSYISICNREIS--PTERCRNRKCHKALROFFDR 210
 Qy 89 GPPALTHALLFCGGCAGCACERRQTAPACAFSGPQLAPPSCIKPLDRERSRRCPRL 148
 Db 211 VPSETYTMFLFCSCQDQACERRQTILPSCSYEDKE--KPNCLDLRSCTDHLCRSRL 268
 Qy 149 FAFOASCAPAPGSRDGCPEGGERPLRAYAGLVGTWTPNLYDN--VSARVAPWGCEAS 206
 Db 269 ADFHANCRASRYTITSCHPADNYOIGSYAGMIGFRDMTPNVDNSNPPTGIVSPWCNGRS 328
 Qy 207 GNRBECFPLKFTRNCPLDGAIAF 233
 Db 329 GNMBEECEKPLRDTENPCLRNAIQAF 355

RESULT 4
 US-09-487-685-6
 Sequence 6, Application US/09487685
 Patent No. 634248

GENERAL INFORMATION:
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
 TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/487,685
 FILING DATE: 19-Jan-2000
 CLASSIFICATION: <Unknown>
 APPLICATION NUMBER: 08/957,063

PRIOR APPLICATION DATA:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 913
 FILING DATE: 18-Feb-1997
 CLASSIFICATION: <Unknown>
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD, Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE DOCKET NUMBER: P1086P2

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 464 amino acids
 TYPE: Amino Acid

TOPOLOGY: Linear
 Query Match 33.2%; Score 469; DB 3; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1.8e-35; 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indexes 6; Gaps 3;

Qy 29 ASSTEGNRCEAECTADEOCQQLSERVEYAQCIGRAGRGPGSCVRSRCAALRFFPAR 88
 Db 153 AVSTKSNHCLDAAKACNLNDCKKURSYISCNREIS--PTERCRKCHKALQFDFR 210

Qy 89 GPPALTHALIFCGCGSPACERRTFAAACAFSGPOLAPPSCLKPLDRCRSRRCRPRL 148
 Db 211 VPSEYYTYRMELFCSCDQACERRTILPSOYEDKE--KPNCLDLRSLCRTDHLCRSRL 268

Qy 149 FAFOQSCAPGSPRGCPERGGPRCIRAYAGLVGTVTPNLDN--VSARVAPWCCAES 206
 Db 269 ADFHANCRASRTITSCPADNYQACIGSAGMIGDMTPVDSNPTGIVVSPWNCRG 328

Qy 207 GNRRECEAFRKLUFPNCPDGA1QAF 233
 Db 329 GNMEECBKFPLDFTENPCLNRAIQAF 355

RESULT 5
 US-08-002-805D-6
 ; Sequence 6, Application US/08802805D
 ; Patent No. 637453
 ; GENERAL INFORMATION:
 ; APPLICANT: Robert D. Klein
 ; TITLE OF INVENTION: Neurturin Receptor
 ; NUMBER OF SEQUENCES: 28
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Genentech, Inc.
 ; STREET: 1 DNA Way
 ; CITY: South San Francisco
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 94080

COMPUTER READABLE FORM:
 COMPUTER TYPE: 3.5 inch, 1.44 MB floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/08802805D
 FILING DATE: 18-Feb-1997
 CLASSIFICATION: 536

ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD., Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEFAX: 650/952-9881
 INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 464 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear

US-08-002-805D-6

Query Match 33.2%; Score 469; DB 3; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1.8e-35; 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indexes 6; Gaps 3;

Qy 29 ASSTEGNRCEAECTADEOCQQLSERVEYAQCIGRAGRGPGSCVRSRCAALRFFPAR 88
 Db 153 AVSTKSNHCLDAAKACNLNDCKKURSYISCNREIS--PTERCRKCHKALQFDFR 210

Qy 89 GPPALTHALIFCGCGSPACERRTFAAACAFSGPOLAPPSCLKPLDRCRSRRCRPRL 148
 Db 211 VPSEYYTYRMELFCSCDQACERRTILPSOYEDKE--KPNCLDLRSLCRTDHLCRSRL 268

Qy 149 FAFOQSCAPGSPRGCPERGGPRCIRAYAGLVGTVTPNLDN--VSARVAPWCCAES 206
 Db 269 ADFHANCRASRTITSCPADNYQACIGSAGMIGDMTPVDSNPTGIVVSPWNCRG 328

Qy 207 GNRRECEAFRKLUFPNCPDGA1QAF 233
 Db 329 GNMEECBKFPLDFTENPCLNRAIQAF 355

RESULT 6
 US-08-861-990-2
 ; Sequence 2, Application US/08861990
 ; Patent No. 6396259
 ; GENERAL INFORMATION:
 ; APPLICANT: Ibanez, Carlos P.
 ; APPLICANT: Aruma, Umas
 ; APPLICANT: Sariola, Hannu
 ; APPLICANT: Suvanto, Petro
 ; APPLICANT: Trupo, Miles
 ; APPLICANT: Saatma, Mart
 ; TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptors
 ; FILE REFERENCE: CEPHO418
 ; CURRENT APPLICATION NUMBER: US/08/08861,990
 ; CURRENT FILING DATE: 1997-05-22
 ; PRIOR APPLICATION NUMBER: 08/747,842
 ; PRIOR FILING DATE: 1996-11-13
 ; PRIOR APPLICATION NUMBER: 60/006,619
 ; PRIOR FILING DATE: 1995-11-13
 ; PRIOR APPLICATION NUMBER: 60/015,767
 ; PRIOR FILING DATE: 1996-04-16
 ; PRIOR APPLICATION NUMBER: 60/021,965
 ; PRIOR FILING DATE: 1996-06-27
 ; PRIOR APPLICATION NUMBER: 60/020,638
 ; PRIOR FILING DATE: 1996-06-27
 ; PRIOR APPLICATION NUMBER: 60/020,639
 ; PRIOR FILING DATE: 1996-06-27
 ; NUMBER OF SEQ ID NOS: 11
 ; SEQ ID NO: 2
 ; LENGTH: 464
 ; TYPE: PRT
 ; ORGANISM: Rattus sp.
 ; US-08-861-990-2

Query Match 33.2%; Score 469; DB 4; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1.8e-35; 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indexes 6; Gaps 3;

Qy 29 ASSTEGNRCEAECTADEOCQQLSERVEYAQCIGRAGRGPGSCVRSRCAALRFFPAR 88
 Db 153 AVSTKSNHCLDAAKACNLNDCKKURSYISCNREIS--PTERCRKCHKALQFDFR 210

Qy 89 GPPALTHALIFCGCGSPACERRTFAAACAFSGPOLAPPSCLKPLDRCRSRRCRPRL 148
 Db 211 VPSEYYTYRMELFCSCDQACERRTILPSOYEDKE--KPNCLDLRSLCRTDHLCRSRL 268

Qy 149 FAFOQSCAPGSPRGCPERGGPRCIRAYAGLVGTVTPNLDN--VSARVAPWCCAES 206
 Db 269 ADFHANCRASRTITSCPADNYQACIGSAGMIGDMTPVDSNPTGIVVSPWNCRG 328

Qy 207 GNRRECEAFRKLUFPNCPDGA1QAF 233
 Db 329 GNMEECBKFPLDFTENPCLNRAIQAF 355

RESULT 7
 US-08-093-316C-6
 ; Sequence 6, Application US/09388316C
 ; Patent No. 6777156
 ; GENERAL INFORMATION:
 ; APPLICANT: KLEIN, ROBERT D.

; APPLICANT: ROSENTHAL, ARNON
 ; APPLICANT: HYNES, MARY A.
 ; TITLE OF INVENTION: NEURTURIN RECEPTOR
 ; FILE REFERENCE: GENENT-45A2D1
 ; CURRENT APPLICATION NUMBER: US/09/388,316C
 ; PRIORITY APPLICATION NUMBER: 07/024,665
 ; PRIORITY FILING DATE: 1998-02-17
 ; PRIORITY APPLICATION NUMBER: 60/063,258
 ; PRIORITY FILING DATE: 1997-10-24
 ; PRIORITY APPLICATION NUMBER: 60/049,818
 ; PRIORITY FILING DATE: 1997-06-09
 ; PRIORITY APPLICATION NUMBER: 60/038,839
 ; SEQ ID NO: 6
 ; LENGTH: 464
 ; TYPE: PRT
 ; ORGANISM: Ratticus norvegicus
 ; US-09-388-316C-6

Query Match 33.2%; Score 469; DB 4; Length 464;
 Best Local Similarity 43.0%; Pred. No. 1.8e-35; Mismatches 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRGVVAEACTADEQOCQLRSBVSYVQCLGRAGWRGSCVRSRCRALRFFAR 88
 Db 153 AVSTKSNHCLDAKACAKNLDNCKKRSYISICNREIS--PTERCNRKCHKALKRQFDR 210

Qy 89 GPPALTHALIFCGEGCACERRQTFAPACAFSGPQLAPPSCIKLDRERSRCPRL 148
 Db 211 VPSEYTRMLFCSCODQACAKERROTILPSCSYDKE--KPNCLDLRSLCRTBLCRSRL 268

Qy 149 FAFOASCAPAPGSRGCGPEEGPRCLRAYAGLVGTUTPNYLN--VSARVADWGCAS 206
 Db 268 329 GNMEEBECEKFIRDFTENPCLNNAIQAF 355

Qy 269 ADFHANCRASYRTITSCPADNYOCLGSYAGMIGFDMTPNVDSNPTGIVVSPWCNGGS 206
 Db 328

RESULT 8
 US-09-957-063-18 Application US/08957-063
 ; Sequence 18, Application US/08957-063
 ; Patent No. 625157
 ; GENERAL INFORMATION:
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes

TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94180

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPain (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/957,063
 FILING DATE: 24-Oct-1997
 CLASSIFICATION: 800
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/871
 FILING DATE: 9-Jun-1997
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 913
 FILING DATE: 18-Feb-1997

; INFORMATION FOR SEQ ID NO: 18:
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 650/952-8674
 ; INFORMATION FOR SEQ ID NO: 18:
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 650/952-8881
 ; INFORMATION FOR SEQ ID NO: 18:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 664 amino acids
 ; TYPE: Amino Acid
 ; TOPOLOGY: Linear
 ; US-08-957-063-18

Query Match 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35; Mismatches 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRGVVAEACTADEQOCQLRSBVSYVQCLGRAGWRGSCVRSRCRALRFFAR 88
 Db 153 AVSTKSNHCLDAKACAKNLDNCKKRSYISICNREIS--PTERCNRKCHKALKRQFDR 210

Qy 89 GPPALTHALIFCGEGCACERRQTFAPACAFSGPQLAPPSCIKLDRERSRCPRL 148
 Db 211 VPSEYTRMLFCSCODQACAKERROTILPSCSYDKE--KPNCLDLRSLCRTBLCRSRL 268

Qy 149 FAFOASCAPAPGSRGCGPEEGPRCLRAYAGLVGTUTPNYLN--VSARVADWGCAS 206
 Db 268

Qy 207 GNRRECECAFRKLFTRNPCLDGATQAF 233
 Db 329 GNMEEBECEKFIRDFTENPCLNNAIQAF 355

RESULT 9
 US-09-487-685-18 Application US/09487685
 ; Sequence 18, Application US/09487685
 ; Patent No. 6343348
 ; GENERAL INFORMATION:
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes

TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94180

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPain (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/487,685
 FILING DATE: 19-Jan-2000
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/957,063
 FILING DATE: <Unknown>
 APPLICATION NUMBER: 913
 FILING DATE: 18-Feb-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD., Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086P2

; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 650/952-8674
 ; INFORMATION FOR SEQ ID NO: 18:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 664 amino acids
 ; TYPE: Amino Acid
 ; TOPOLOGY: Linear
 ; US-08-957-063-18

Query Match 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 29 ASSTEGNIGCVERAEEACTADEQOCQOLRSVYAOCLGRAGWRGPSCVSRCRALRPAR 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 153 AVSTKSNHCLDAKACNLNDCKKLSSYISICNRREIS--PTERCNRKCHKALRQFDR 88
 29 GPPALTHALLFCGCGECPACACERRQTPAPACFLSGPQLAPPSCLKPLDRCRSRCPRL 148
 211 VPSBYTYRMFLFCSCDQCAERRQTLIPSCSYEDKE--KPNCLDLRSLCRDLHCSRL 268

Db 149 FAFOQASCAPAPSRSRGCGPEEGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEAS 206
 269 ADPHANCRASYRTITSCTPADNYOACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNRGS 328

Qy 207 GNRREECEAFRKLFTRNCLDGA1QAF 233
 329 GMNEECEKFRLDFTENPCLRN1QAF 355

RESULT 10 US-08-802-805D-18
 Sequence 18, Application US/08802805D
 Patent No. 6372453

GENERAL INFORMATION:
 APPLICANT: Robert D. Klein
 TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 28
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08-802, 805D
 FILING DATE: 18-Feb-1997
 CLASSIFICATION: 535
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD, Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEX/FAX: 650/952-9881
 INFORMATION FOR SEQ ID NO: 18:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 664 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear

US-08-802-805D-18

Query Match 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 89 GPPALTHALLFCGCGECPACACERRQTPAPACFLSGPQLAPPSCLKPLDRCRSRCPRL 148
 211 VPSBYTYRMFLFCSCDQCAERRQTLIPSCSYEDKE--KPNCLDLRSLCRDLHCSRL 268

Db 149 FAFOQASCAPAPSRSRGCGPEEGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEAS 206
 269 ADPHANCRASYRTITSCTPADNYOACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNRGS 328

Qy 207 GNRREECEAFRKLFTRNCLDGA1QAF 233
 329 GMNEECEKFRLDFTENPCLRN1QAF 355

RESULT 11 US-09-388-316C-18
 Sequence 18, Application US/09388316C
 Patent No. 6777196

GENERAL INFORMATION:
 APPLICANT: KUBLIN, ROBERT D.
 APPLICANT: ROSENTHAL, ARNON
 APPLICANT: HYNE, MARY A.
 TITLE OF INVENTION: NEURTURIN RECEPTOR
 FILE REFERENCE: GENENT-45A2V1
 CURRENT APPLICATION NUMBER: US/09/388,316C
 PRIORITY FILING DATE: 1999-09-01
 PRIORITY FILING DATE: 1997-10-24
 PRIORITY FILING DATE: 1998-02-17
 PRIORITY FILING DATE: 1998-02-18
 PRIORITY FILING DATE: 1997-02-18
 PRIORITY APPLICATION NUMBER: 60/063, 258
 NUMBER OF SEQ ID NOS: 30
 SOFTWARE: FASTSEQ for Windows Version 4.0
 SEQ ID NO: 18
 LENGTH: 664

TYPE: PRT
 FEATURE:
 ORGANISM: Artificial sequence
 OTHER INFORMATION: This sequence is a fusion protein comprising rat
 OTHER INFORMATION: NTM1alpha sequence and human FC sequence.

US-09-388-316C-18

Query Match 33.2%; Score 469; DB 4; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 29 ASSTEGNIGCVERAEEACTADEQOCQOLRSVYAOCLGRAGWRGPSCVSRCRALRPAR 88
 153 AVSTKSNHCLDAKACNLNDCKKLSSYISICNRREIS--PTERCNRKCHKALRQFDR 210
 211 VPSBYTYRMFLFCSCDQCAERRQTLIPSCSYEDKE--KPNCLDLRSLCRDLHCSRL 268

Db 149 FAFOQASCAPAPSRSRGCGPEEGPRCLRAYAGLVGTWTPNLDN--VSARVAPWCGEAS 206
 269 ADPHANCRASYRTITSCTPADNYOACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNRGS 328

Qy 207 GNRREECEAFRKLFTRNCLDGA1QAF 233
 329 GMNEECEKFRLDFTENPCLRN1QAF 355

RESULT 12 US-09-187-906-9
 Sequence 9, Application US/09187906
 Patent No. 667135

GENERAL INFORMATION:
 APPLICANT: BIOCEN, INC.
 TITLE OF INVENTION: Ret. Ligand (RetL) for Stimulating Neural
 and Renal Growth

NUMBER OF SEQUENCES: 21
 CORRESPONDENCE ADDRESS:
 ADDRESSE: Biogen, Inc.
 STREET: 14 Cambridge Center
 CITY: Cambridge
 STATE: MA
 COUNTRY: USA
 ZIP: 02142
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/187,906
 FILING DATE:
 CLASSIFICATION:
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: PCT/US97/07726
 FILING DATE: 07-MAY-97
 APPLICATION NUMBER: US 60/017,427
 FILING DATE: 09-MAY-96
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/019,300
 FILING DATE: 07-JUN-96
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/021,859
 FILING DATE: 16-JUL-96
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/043,533
 FILING DATE: 10-AUG-97
 ATTORNEY/AGENT INFORMATION:
 NAME: Kaplan, Warren A.
 REGISTRATION NUMBER: 34,199
 REFERENCE/DOCKET NUMBER: A008 PCT CIP
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617-679-2400
 TELEFAX: 617-679-2838
 INFORMATION FOR SEQ ID NO: 9:
 LENGTH: 346 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-09-187-906-9

Query Match 32.9%; Score 465; DB 4; Length 346;
 Best Local Similarity 41.9%; Pred. No. 4.3e-35;
 Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

Qy 33 EGNRVEAEEACTADBDQCOOLRSVYVACQCLGRAGWRGPGSCVRSRCAALRFPRARGPPA 92
 Db 145 KGNNDAAKCNLDDICKYRSAYITPCTSV--SNDVCRNRKCHGAIQFFDKVPAK 201
 Qy 93 LTHALLFCCGEGPACAAERRTQFAPACFSGPOLAPPCKLPDRCBERSRRCPPLRFQ 152
 Db 202 HSIGMLFCSDRDLACTERKRQTIVPCKE--EREKPNLNLODSCCKNYICKSLADFF 259

Qy 153 ASCAPAPGSRDGCPBEGSPRLAYAGLVGTUTPVMDVNSARVAPPGCEASNRRE 212
 Db 260 TNQOPESRSVSSCILKENTADCLLAYSGLTGWTMPNVDSSLSVAPWCDCSNSNDIIE 319
 Qy 213 CEARKLFLTRNPCLDGAQAFDSQSPSTLQDQWNP 247
 Db 320 CLKFLNPKDNTCLNAIQAFGNGSDVTW--WQP 351

RESULT 14
 US-09-187-906-11
 Sequence 11, Application US/09187906
 Patent No. 6677135
 GENERAL INFORMATION:
 APPLICANT: Biogen, Inc.
 TITLE OF INVENTION: Ret Ligand (Ret) for Stimulating Neural
 NUMBER OF SEQUENCES: 21
 CORRESPONDENCE ADDRESS:
 ADDRESSE: Biogen, Inc.
 STREET: 14 Cambridge Center
 CITY: Cambridge
 STATE: MA
 COUNTRY: USA
 ZIP: 02142
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

RESULT 13
 US-09-1805D-22
 Sequence 22, Application US/0802805D
 Patent No. 6372453
 GENERAL INFORMATION:
 APPLICANT: Robert D. Klein

SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/187,906
FILING DATE: 07-MAY-97
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: PCT/US97/07726
FILING DATE: 07-MAY-97
APPLICATION NUMBER: US 60/017,427
FILING DATE: 08-MAY-96
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 60/019,300
FILING DATE: 07-JUN-96
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 60/021,859
FILING DATE: 16-JUL-96
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 60/043,533
FILING DATE: 10-APR-97
ATTORNEY/AGENT INFORMATION:
NAME: Kaplan, Warren A.
REGISTRATION NUMBER: 34,199
REFERENCE/DOCKET NUMBER: A008 PCT CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-679-2400
TELEFAX: 617-679-2838
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 460 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-187-906-11

SEQ ID NO 10
LENGTH: 463
TYPE: PRT
ORGANISM: HUMAN
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5) .. (5)
OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
NAME/KEY: misc_feature
LOCATION: (1) .. (537)
OTHER INFORMATION: No. 6455277ee="1 to 537 is -235 to 301 of Figure 5 21aacm"
NAME/KEY: misc_feature
LOCATION: (550) .. (550)
OTHER INFORMATION: N in position 550 indicates any nucleic acid

Query Match 32.9%; Score 465; DB 4; Length 463;
Best Local Similarity 41.9%; Pred. No. 4.3e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

Qy 33 EGNRCWEAAACTAEDBOQOLRSEVYQAQIGRAGWRGPESCCRRLRREFARGPPA 92
Db 150 KGNNCIDAAKCNLUDICKRKRSAYITPCITSV--SNDVCNRRKCHKAHQFFDKVPAK 206
Qy 93 LTHALIFCGGEGPACAERRQTFAACAFSGPQLAPPSCUKPLURCERSRRRPLFAO 152
Db 207 HSYGMFCSCRDIACTTERQTIVCSTE--ERBKPKNCNLQPSCKTNYCIRSLADFP 264
Qy 153 ASCRAPAPGSRDGCPEEGPRCLRAYAGLVGTVTPNLYDNWSARVAPWCCGEASGRREE 212
Db 265 TNQCPERSVSVSCLKENYADCLLAYSGLGTWTPTNVISSLSLSPAWPCDCCNSNDLEE 324
Qy 213 CEARFLKFTRNPICLDGAQAFDDSQPSVQDQWNP 247

Db 325 CLKFLNPKDNTCLKNAIQARGNGSDVTW
Search completed: January 26, 2005, 13:25:13
Job time : 41 BECS



GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 26, 2005, 12:53:26 ; Search time 158 Seconds
(without alignments)
585.773 Million cell updates/sec

Title: US-10-019-337E-9
Perfect score: 1413
Sequence: 1 MLSCAYLRLVTLNRPQGAIVW.....SVLQDQWMNPYQNAQGQAKTEA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqB, 35872999 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:**

1: geneseqDP1980s:**
2: geneseqDP1990s:**
3: geneseqDP2000s:**
4: geneseqDP2001s:**
5: geneseqDP2002s:**
6: geneseqDP2003as:**
7: geneseqDP2003bs:**
8: geneseqDP2004s:**

Pred. No. 18 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and 18 derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Match Length DB ID Description

Result No.	Score	Query	Match	Length	DB ID	Description
1	1413	100.0	258	4	ABB1637	Aab61637 Rat GFRalpha1
2	1386	98.1	273	4	ABB1636	Aab61636 Rat GFRalpha1
3	1078	76.3	277	4	ABB2103	Aab62103 Mouse Ret
4	1078	76.3	476	4	ABB2107	Aab62107 Murine Ret
5	1075.5	76.1	260	4	ABB2106	Aab62106 Mouse Ret
6	1075.5	76.1	260	4	ABB09214	Abb09214 Mouse GFRalpha1
7	1075.5	76.1	293	4	ABB09215	Abb09215 Mouse put
8	1028.5	72.8	264	4	ABB2104	Aab62104 Mouse Ret
9	927	65.6	340	4	AV42771	Avy42771 Murine gfr
10	920.5	65.1	269	4	ABB09217	Abb09217 Human GFRalpha1
11	914.5	64.7	282	4	ABB62105	Aab62105 Human Ret
12	767.5	54.3	299	4	ABB09218	Abb09218 Human put
13	649.5	46.0	182	4	ABB09219	Abb09219 Human put
14	59.5	40.3	190	4	ABB09216	Abb09216 Mouse sec
15	515	36.4	132	5	ABB72385	Abb05369 Mouse Gdnfr
15	515	36.4	460	2	AVB84181	Abb72385 Murine pr
17	469	33.2	464	2	AVB71602	Abb092105 Human Ret
18	469	33.2	464	2	AVB92299	Abb092102 Rat neurt
19	469	33.2	464	2	AVB80122	Abb092299 Rat GDNFR
20	469	33.2	464	3	AVB80122	Avy80122 Rat neurt
21	469	33.2	464	5	ABB79036	Abb79036 Rat neurt
22	469	33.2	464	5	ABB09630	Abb09630 Amino acid
23	469	33.2	464	5	AVB79266	Aau79266 Rat neurt
24	469	33.2	464	7	ADD11657	Add11657 Rat neurt
25	33.2				ADBS54591	Ades54591 Rat Prote

ALIGNMENTS

RESULT 1
ID AAB61637 standard; protein; 258 AA.
XX
AC AAB61637;
XX
DT 06-APR-2001 (first entry)
DB Rat GFRalpha-4 splice variant B.
XX
KW Rat; GFRalpha-4; carcinoma; familial hirschsprung disease; pain; glial cell-line derived neurotrophic factor; neurodegenerative disease; GDNF family receptor alpha-4; Alzheimer's disease; Parkinson's disease; motor neuron disease; peripheral neuropathy; spinal cord injury; chromosome 3q36.
XX
OS Rattus rattus.
XX
PN WO200102557-A1.
XX
PD 11-JAN-2001.
XX
PR 26-MAY-2000; 2000WO-EP004918.
XX
PR 29-JUN-1999; 99GB-00015200.
XX
PA (JANSSEN) JANSSEN PHARM NV.
XX
PI Masure SLJ, Cik M, Hoefnagel EW,
XX
WPI: 2001-138137/14.
DR N-PSDB; AA31061, AFM31063.
XX
PT Gial cell-line derived neurotrophic factor family receptor alpha-4, useful for preparing medicaments for treating neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.
XX
PS Claim 14; Page 74-75; 82pp; English.
XX
CC The present sequence is rat Gial cell-line Derived Neurotrophic Factor (GDNF) family receptor alpha-4 (GFRalpha-4) splice variant B. GFRalpha-4 is useful in the preparation of a medicament for the treatment of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, motor neuron disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, carcinomas, and diseases associated with GFRalpha-4 receptor dysfunction and in alleviating pain. The rat GFRalpha-4 gene (see AF31061) is localized on chromosome 3q36.
XX

SQ	Sequence 258 AA;
Query Match	100 %; Score 1413; DB 4; Length 258;
Best Local Similarity	100.0%; Pred. No. 2.1e-123;
Matches	258; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MLSGAYLRLVNERPGQAVWLSLGCGQSASSTEGNCVVEAECTADEQCQQLRSSEYYAQ 60
Db	1 MLSGAYLRLVNERPGQAVWLSLGCGQSASSTEGNCVVEAECTADEQCQQLRSSEYYAQ 60
QY	61 CIGRAGMGRGPSCVVRCCRRLRFFARGPPLTHALIFCGCEGPAERRROTAPACA 120
Db	61 CIGRAGMGRGPSCVVRCCRRLRFFARGPPLTHALIFCGCEGPAERRROTAPACA 120
QY	121 FSGQOLAPPSCILKPLDRERSRRCRPLFQASCPAEGSRDGCPEEGPRCIRAYAGL 180
Db	121 FSGQOLAPPSCILKPLDRERSRRCRPLFQASCPAEGSRDGCPEEGPRCIRAYAGL 180
QY	181 VGTIVTPNLDNTSARVAPWCGEASGNRRECEAFRKLFTRNPCLDGAIQAFDSSQPSV 240
Db	181 VGTIVTPNLDNTSARVAPWCGEASGNRRECEAFRKLFTRNPCLDGAIQAFDSSQPSV 240
QY	241 LQDQWNPYQNAQGQKTEA 258
Db	241 LQDQWNPYQNAQGQKTEA 258
RESULT 2	
ID	AAB61636
ID	AAB61636 standard; protein; 273 AA.
AC	AAB61636;
XX	
XX	06-APR-2001 (first entry)
XX	Rat GFRalpha-4 splice variant A.
KW	Rat; GFRalpha-4; carcinoma; familial hirschsprung disease; pain; glial cell-line derived neurotrophic factor; neurodegenerative disease; GDNP family receptor alpha-4; Alzheimer's disease; Parkinson's disease; motor neuron disease; peripheral neuropathy; spinal cord injury; chromosome 3q6.
KW	Rattus rattus.
XX	WO200102557-A1.
XX	
PD	11-JAN-2001.
XX	
PF	26-MAY-2000; 2000WO-EP004918.
XX	
PR	29-JUN-1999; 99GB-00015200.
XX	
PA	(JANCS) JANSSEN PHARM NV.
XX	
PI	Masue SLJ, Cik M, Hoefnagel EW;
XX	
DR	WPI; 2001-138137/14.
XX	
N-PSDB;	AAF31061, AAF31062.
XX	
PT	Gliaal cell-line derived neurotrophic factor family receptor alpha-4, useful for preparing medicaments for treating neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.
PS	Claim 14; Page 73-74; 82pp; English.
CC	The present sequence is rat Glial cell-line Derived Neurotrophic Factor (GNF) family receptor alpha-4 (GFRalpha-4) splice variant A. GFRalpha-4 is useful in the preparation of a medicament for the treatment of a tumor neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, motor neuron disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, carcinomas, and diseases associated with GFRalpha-4 receptor dysfunction and in alleviating pain. The rat-GFRalpha-4 gene
CC	(see AAF31061) is localised on chromosome 3q35
XX	Sequence 273 AA;
SQ	
Query Match	98.1%; Score 1386; DB 4; Length 273;
Best Local Similarity	100.0%; Pred. No. 7.5e-11;
Matches	252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MLSGAYLRLVNERPGQAVWLSLGCGQSASSTEGNCVVEAECTADEQCQQLRSSEYYAQ 60
Db	1 MLSGAYLRLVNERPGQAVWLSLGCGQSASSTEGNCVVEAECTADEQCQQLRSSEYYAQ 60
QY	61 CIGRAGMGRGPSCVVRCCRRLRFFARGPPLTHALIFCGCEGPAERRROTAPACA 120
Db	61 CIGRAGMGRGPSCVVRCCRRLRFFARGPPLTHALIFCGCEGPAERRROTAPACA 120
QY	121 FSGQOLAPPSCILKPLDRERSRRCRPLFQASCPAEGSRDGCPEEGPRCIRAYAGL 180
Db	121 FSGQOLAPPSCILKPLDRERSRRCRPLFQASCPAEGSRDGCPEEGPRCIRAYAGL 180
QY	181 VGTIVTPNLDNTSARVAPWCGEASGNRRECEAFRKLFTRNPCLDGAIQAFDSSQPSV 240
Db	181 VGTIVTPNLDNTSARVAPWCGEASGNRRECEAFRKLFTRNPCLDGAIQAFDSSQPSV 240
QY	241 LQDQWNPYQNAQG 252
Db	241 LQDQWNPYQNAQG 252
RESULT 3	
ID	AAB62103
ID	AAB62103 standard; protein; 277 AA.
XX	
AC	AAB62103;
XX	
DT	29-MAY-2001 (first entry)
XX	
DE	Mouse RetL5 polypeptide.
XX	
KW	Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic; Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse; vulnerability; nootropic; anti-HIV; neuroprotective; antibacterial; cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic; OS
KW	Mus sp.
XX	
FH	Location/qualifiers
FT	peptide 1..21
FT	/note= "signal peptide"
FT	Protein 22..277
FT	/note= "mature protein"
XX	
PN	WO200116169-A2.
XX	
PD	08-MAR-2001.
XX	
PF	01-SEP-2000; 2000WO-US024111.
XX	
PR	01-SEP-1999; 99US-0152024P.
XX	
PA	(BIO) BIOTRON INC.
XX	
PI	Wekey D;
XX	
WPI	WPI; 2001-235091/24.
DR	N-PSDB; AAF57270.
XX	
PT	Novel Ret ligand polypeptide useful for suppressing growth of a tumor cell that expresses Ret and for modulating Ret signal transduction involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
XX	
PS	Claim 13; Fig 3; 76pp; English.
XX	

XX
 KW Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotoxic;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 XX
 OS Mus sp.
 XX WO200116169-A2.
 XX 08-MAR-2001.
 XX PR 01-SEP-1999; 99US-0152024P.
 XX PA (BIOJ) BIOPEN INC.
 PT Worley D;
 XX DR WPI; 2001-235091/24.
 DR N-PSDB; AAI57273.
 XX PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 PS Disclosure; Fig 8; 76pp; English.

The invention relates to mouse and human Ret ligand 5 (RetL5),
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 dimerization or autoprophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 Ret expressing tissue in a subject, for suppressing growth of a tumor
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC protein containing RetL5 and antibodies are useful for stimulating renal
 tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 acute renal failure, acute nephritis, chronic renal failure, nephrotic
 syndrome, renal tubule defects, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 such as neural degeneration where neural growth and regeneration are
 desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents an alternatively spliced mouse
 CC RetL5 polypeptide
 XX Sequence 260 AA;

Query Match 76.1%; Score 1075.5; -DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92; Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;
 QY 27 GSASSTEGNRVCVEAAEACTADEOQCOLRSVVAQCLGRA--GWRGPSCVSRCCRRLR 83
 DB 16 GSASFDTDGNRVCVDAAEACTADERCOQLRSVVAQCLGRAAPGGRRGPGGCVRSRRRLR 75
 QY 84 RFFEARGPPLATHALFCGEGPACHERROTAPACAFSGPQLAPPSCIKPLCERERR 143
 DB 76 RFFFARGPPPLATHALFCGEGSACERAQRTTAPACASGSGPGLVPPSCIEPLRCERSL 135
 QY 144 CRPRFLFAQASCAPAPSGSRDGCSPBEGGPRCLRAYAGLVGCVVVTNYLDNSARVAPWGC 203
 DB 136 CRPRFLAQASCAPAPSGSRDGCSPBEGGPRCLRAYAGLVGCVVTPNLYLDNSARVAPWGC 195
 XX Sequence 260 AA;

Query Match 76.1%; Score 1075.5; -DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92; Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;
 QY 27 GSASSTEGNRVCVEAAEACTADEOQCOLRSVVAQCLGRA--GWRGPSCVSRCCRRLR 83
 QY Sequence 260 AA;

QY 204 EASGNRREECAFRLKPTRNPCLGAIQARDSSQPSVLDQ 244
 DB ABB0214 RESULT 6
 ID ABB0214 standard; protein; 260 AA.
 PN XX
 XX ABB0214;
 AC XX
 PD XX
 DT 08-JUL-2002 (first entry)
 DE Mouse GPI-anchored isoformal protein SEQ ID NO:1.
 PR XX
 PA GFRalpha4; glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medillary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.
 OS Mus musculus.
 XX WO2001162795-A1.
 XX 30-AUG-2001.
 PD XX
 XX 14-NOV-2000; 2000WO-FI000994.
 PR XX
 PR 21-FEB-2000; 20000FI-00000394.
 DR XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Airaksinen M, Sharma M, Poteriaev D, Lindahl M, Timmusk T;
 PI ROSSI J;
 XX WPI; 2001-596722/67.
 DR N-PSDB; ABL51663.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancer comprises a cDNA encoding a splicing isoform of
 PR mammalian growth factor Receptor (GFR)alpha4.
 XX
 PS Claim 9; Fig 18; 143pp; English.
 XX
 The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteoprotective, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRalpha 4 protein, designated GPI-anchored
 isoform al, from the present invention
 XX Sequence 260 AA;

Db 16 GSASFTDGNRCVDAEACTADBERCQQLRSEYVYARCLGRAPGGRPGPGCVRSRRALR 75
Qy RFFARGPDPALHALLFGCGCEGACERROTAPACAFSGPQLAPSCKLKDRCRSRR 143
Db 76 RFFARGPDPALHALLFGCGCEGACERROTAPACAFSGPGLVPSCLERCRSRL 135
Qy 144 CRPLFLFQASCAPAGPSDRGCGPEEGPRCIRAYAGLVGTWTTPNLDNVNSARVAPWGC 203
Db 136 CRPLLFQASCAPAPSRDRGCGPEEGPRCIRAYAGLVGTWTTPNLDNVNSARVAPWGC 195
Qy 204 EASGNRRECECAFRLKFLTRNCIDGAQAFSSQPSVLUQDQ 244
Db 196 AASGNRRECECAFRLKFLTRNCIDGAQAFSSQPSVLUQDQ 236

RESULT 7
ABB0215
ID ABB0215 standard; protein; 293 AA.
XX
AC ABB0215;
XX
DT 08-JUL-2002 (first entry)
XX
DE Mouse putative transmembrane isoform a2 protein SEQ ID NO:2.
XX
KW GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
KW glycosyl-phosphatidylinositol-linked GPNP family alpha-receptor;
KW glial cell line derived neurotrophic factor; osteopathic; tumour;
KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
KW neuronal disorder; aberrant axonal sprouting.
OS Mus musculus.
XX
PN WO200162795-A1.
PD 30-AUG-2001.
XX
PP 14-NOV-2000; 2000WO-FI000994.
XX
PR 21-FEB-2000; 2000FI-0000394.
XX
PA (LICE-) LICENTIA LTD.
XX
PI Airaksinen M, Saarma M, Poteraev D, Lindahl M, Timmusk T;
PT Rossi J;
XX
DR DR N-PSDB; ABIS1670.
XX
PT New nucleic acid sequence for manufacturing polypeptides for treating
PT endocrine cancers comprises a cDNA encoding a splicing isoform of
PT mammalian growth factor receptor (GFR)alpha4.
PS claim 9; FIG 19B; 143pp; English.

The present invention describes an isolated and purified cDNA sequence
encoding a splicing isoform of a mammalian growth factor receptor
(GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
neurotrophic factor (GDNF) family alpha receptor. A GFRalpha4
signalling in neurons or endocrine cells such as thyroid calcitonin-
producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
polynuclearoid sequences can be used for recording GFRalpha4 protein and
useful for diagnosing and/or treating tumours in parathyroid gland cells,
adrenal chromaffin cells, cells of pituitary intermediate lobe,
neoplasia, endocrine tumours, medullary thyroid carcinoma and
pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
preventing neuronal death or aberrant axonal sprouting. The present
sequence represents the mouse GFRalpha 4 protein, designated putative

CC transmembrane isoform a2, from the present invention
XX
SQ Sequence 293 AA;

Query Match 76.1%; **Score** 1075.5; **DB** 4; **Length** 293;
Best Local Similarity 89.5%; **Pred.** No. 7; 7.e-92; **Indels** 3; **Gaps** 1;
Matches 198; **Conservative** 7; **Mismatches** 13; **DB** 4; **Length** 293;
AC ABB0215;
XX
DT 29-MAY-2001 (First entry)
XX
DB Mouse RetL5 polypeptide.
XX
KW Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
XX
OS Mus sp.
XX
PH Key Location/Qualifiers
PT Peptide 1..21
PT /note= "signal peptide"
PT Protein 22..264
PT /note= "mature protein"
XX
PN WO200116169-A2.
XX
PD 08-MAR-2001.
XX
PP 01-SEP-2000; 2000WO-US024111.
XX
PR 01-SEP-1999; 99US-0152024P.
XX
PA (BIOJ) BIOPRO INC.
XX
PT Worley D;
XX
DR DR N-PSDB; AAF57271.
XX
PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
cell that expresses Ret and for modulating Ret signal transduction
PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
XX
PS Claim 13; Fig 4; 76pp; English.

The invention relates to mouse and human Ret ligand 5 (RetL5)
polypeptides. The RetL5 polypeptides can be expressed by standard
recombinant methodology. The RetL5 when bound to Ret, acts as a
dimerization or autophosphorylation activator. The polypeptides and their

CC antibodies are useful for stimulating growth of or limiting damage to.
 CC Ret expressing tissue in a subject, for suppressing growth of a tumour
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tube defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 CC such as hemorrhage or emboli, and neural disorders such as mental and cerebral
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents the mouse RetL5 polypeptide
 CC predicted from DSW300 sequence by GENESCAN/GENE ALEx
 XX SQ Sequence 264 AA:

Query Match 72.8%; Score 1028.5; DB 4; Length 264;

Best Local Similarity 86.9%; Pred. No. 1.16e-87; Matches 192; Conservative 7; Mismatches 13; Indels 9; Gaps 2;

Db 16 GSASFTDGNRCRDAAEACTADBCQOQURSEVQAQCLGIGA--GWRGPSCVRSRRALR 83
 Qy ||||| :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 84 RFFARGPAPALTHALFGCGCAGCACERRQTAPACAFSPEQLAPSCLPLDRERSR 143
 Qy |||||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 76 RFFARGPAPALTHALFGCGCAGCACERRQTAPACAFSPEQLAPSCLPLERCRSL 135
 Qy 144 CRPLILAFQASCAPAPSGRDCPCEGGPRCRAVAGLVGTWTPNLDNSARVAPWGC 203
 Db |||||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Qy 136 CR-----CASCAPAPSGRDCPCEGGPRCRAVAGLVGTWTPNLDNSARVAPWGC 189
 Db 204 EASGNRREECEAFKLFTRCPIDGAIQAFDSQPSVLQDQ 244
 Db 190 ASGNRREECEAFKLFTRCPIDGAIQAFDSQPSVLQDQ 230

RESULT 9
 AAY42771

ID AAY42771 standard; protein; 340 AA.
 AC AAY42771;
 XX DT 05-JAN-2000 (first entry)

DE Murine glial derived neurotrophic factor receptor-alpha-X protein.
 XX
 KW Glial derived neurotrophic factor-alpha-X; GFR-alpha-X; neural cell;
 KW survival; function; nervous system; signalling; diagnosis; treatment;
 KW neurological disorder; sensory disorder; Dejerine-Roussy syndrome;
 KW contralateral anaesthesia; eating disorder; obesity; motor disorder;
 KW Parkinson's disease; amyotrophic lateral sclerosis; ALS;
 KW cognitive disorder; Alzheimer's disease.
 OS Mus sp.

FH Location/Qualifiers
 FT Key Difference 201 /note= "Encoded by ANG"
 FT Misc-difference 217 /note= "Encoded by AAN"
 FT Misc-difference 340 /note= "Encoded by TG"
 XX PN WO9502984A1.

XX PDD 07-OCT-1999.

XX 25-MAR-1999; 99WO-US006631.
 PR 31-MAR-1998; 98US-0080070P.

XX (MILLI-) MILLENNIUM PHARM INC.
 PR Moore KJ;
 DR WPI; 1999-591276/50.
 DR N-PSDB; AA228259.

XX PR A nucleic acid molecule that encodes GDNF Family Receptor alpha-X
 PR protein, methods of isolation and antibodies - useful for the detection
 PR of homologues and identification of binding compounds.

XX Claim 1; Fig 1; 100pp; English.

This sequence represents murine glial derived neurotrophic factor receptor-alpha-X (GFR-alpha-X) protein. GFR-alpha-X is a fourth member of the glial derived neurotrophic (GFR-alpha) family of receptors. The cDNA was identified in a positional cloning process in which the mouse mahogany locus was being sequenced to identify genes involved in obesity. The GFR-alpha-X protein binds to neurotrophic factors such as GDNF (glial cell line-derived neurotrophic factor) and/or NTN (neurturin), and mediates signalling within cells expressing the GFR-alpha-X protein. GFR-alpha-X, like the other three members of the GFR-alpha family (GFR-alpha-1, -2, and -3), transmits a signal to the interior of a cell by activation of the RET protein tyrosine kinase signalling pathway.

Neurotrophic factors promote survival and function of neural cells. Of both the central and peripheral nervous systems. Modulation of GFR-alpha-X activity can result in modulation of the neurotrophic factor-initiated cell function. Probes and/or primers derived from GFR-alpha-X cDNA, and antibodies against the protein are used to detect the presence of GFR-alpha-X nucleic acids or protein and can be used in the diagnosis and treatment of a variety of neurological disorders, including sensory and certain eating disorders (e.g., Dejerine-Roussy syndrome, contralateral anaesthesia, and amytrophic lateral sclerosis), motor disorders (e.g., Parkinson's disease, Alzheimer's disease). In addition, compounds which bind to GFR-alpha-X may be used to modulate the activity of the protein.

XX SQ Sequence 340 AA;

Query Match 65.6%; Score 927; DB 2; Length 340;
 Best Local Similarity 68.2%; Pred. No. 6.3e-78; Matches 180; Conservative 10; Mismatches 28; Indels 46; Gaps 3;

Db 19 GSASFTDGNRCRDAAEACTADBCQOQURSEVQAQCLGIGA--GWRGPSCVRSRRALR 83
 Qy ||||| :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 84 RFFARGPAPALTHALFGCGCAGCACERRQTAPACAFSPEQLAPSCLPLDRERSR 143
 Qy |||||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 79 RFFARGPAPALTHALFGCGCAGCACERRQTAPACAFSPEQLAPSCLPLERCRSL 138
 Qy 144 CRPLILAFQASCAPAPSGRDCPCEGGPRCRAVAGLVGTWTPNLDNSARVAPWGC 203
 Db 139 CRPLILAFQASCAPAPSGRDCPCEGGPRCRAVAGLVGTWTPNLDNSARVAPWGC 198
 Qy 204 EASGNRREECEAFKLFTRCPIDGAIQAFDSQPSVLQDQ 244
 Db 199 AAXWKPARMSLQDALYXGTPAWRGPGGPGRMSVAQSOKLUPGPWVLTFSHHWVGCRW 258
 Qy 224 ---PCLDGAIQAFDSQPSVLQDQ 244
 Db 259 TVCTCHDAIQAQFDSDQPSVLQDQ 282

RESULT 10
 ABB09217

ID	ABB09217	standard; protein; 269 AA.	XX
AC			AC
DT	08-JUL-2002	(first entry)	DT
DE	Human GPI-anchored isoform a protein SEQ ID NO:4.		DE
XX	GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic; glycolyl-phosphatidylinositol-linked GDNF family alpha-receptor; glial cell line derived neurotrophic factor; osteopathic; tumour; neurprotective; anticonvulsant; neoplasia; endocrine tumour; medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; neuronal disorder; aberrant axonal sprouting.		XX
KW	Homo sapiens.		KW
OS			OS
XX	XX		XX
PN	WO20162795-A1.		PN
PD	30-AUG-2001.		PD
PT	AIRAKAINEN M, Saarma M, Poteraiav D, Lindahl M, Timmusk T;		PT
PI	Rossi J;		PI
XX	14-NOV-2000; 2000WO-FI000994.		XX
PR	21-FEB-2000; 2000FI-0000334.		PR
PA	(LICB-) LICENTIA LTD.		PA
XX	Alrakainen M, Saarma M, Poteraiav D, Lindahl M, Timmusk T;		XX
PT	Airakainen M, Saarma M, Poteraiav D, Lindahl M, Timmusk T;		PT
PI	Rossi J;		PI
XX	WPI; 2001-596722/67.		XX
DR	N-PSDB; ABL51672.		DR
PS	Claim 9; Fig 21B; 143pp; English.		PS
XX	New nucleic acid sequence for manufacturing polypeptides for treating endocrine cancers comprises a cDNA encoding a splicing isoform of mammalian growth factor receptor (GFR)alpha4.		XX
CC	The present invention describes an isolated and purified cDNA sequence encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, osteopathic, neurprotective and anticonvulsant activities. GFRalpha4 is a glycosyl-phosphatidylinositol (GPI-linked) glial cell line-derived polynucleotide factor (GPNF) family alpha-receptor. A GFRalpha4 polymeric sequence can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, signalling in neurons or endocrine cells such as thyroid calcitonin-producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotide sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for preventing neuronal death or aberrant axonal sprouting. The present sequence represents the human GFRalpha 4 protein, designated GPI-anchored isoform a, from the present invention		CC
CC	XX		CC
CC	Sequence 269 AA;		CC
Query	Match	65.1%; Score 920.5; DB 4; Length 269; Best Local Similarity 78.3%; Pred. No. 1-9e-77; Matches 173; Conservative 11; Mismatches 34; Indels 3; Gaps 1;	Query
OY	27 GSASSTSGNRCTTAACTAATDSDQCOQKRSYVQAGLGRGWRGPGSCYTSRCRRLRRP 86		OY
Db	16 GSASSVGNSRNCRVDAEACTADARQQLRSYVQAGLGRG--AOGCPEPARCRRLRRP 72		Db
OY	87 ARCPPLAUHALLFCGCGPACABRRQTPAPACPSGQPLAPSSKKPLDRCSRRCR 146		OY
Db	73 ARCPPLAUHALLFCGCGPACABRRQTPAPACPSGQPLAPSSKKPLDRCSRRCR 132		Db
OY	147 RLPAFOQSCAPAPGSRDGCPEEGGPRCLURAYAGIVGTWVTPNVDNSARVAPWGCEAS 206		OY
RESULT 1	133 RLLARQVSCTBAPSABDGCLLDQGARCLRAYAGLVRATVNYVDNVSVARVAPWCDGGS 192		Result
ID	AAB62105		ID
XX	AAB62105 standard; protein; 282 AA.		XX
AC	AAB62105;		AC
XX	XX		XX
DT	29-MAY-2001 (first entry)		DT
DE	Human Ret5 polypeptide.		DE
XX	XX		XX
KW	Ret ligand 5; Ret5; autophosphorylation; tumour; renal; nephrotropic; Alzheimer's disease; Parkinson's disease; Huntington's disease; human; pulmonary; nootropic; anti-HIV; neuroprotective; antibacterial; cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.		KW
XX	Hom sapiens.		OS
XX	XX		XX
PA	Key Location/Qualifiers		PA
PT	Peptide 1..20		PT
FT	/note= "signal peptide"		FT
FT	21..282		FT
FT	/note= "mature protein"		FT
XX	W0200116169-A2.		XX
XX	08-MAR-2001.		PD
XX	01-SEP-2000; 2000WO-US024111.		PP
XX	WPI; 2001-235091/24.		XX
DR	01-SEP-1999; 99US-0152024P.		PR
DR	N-PSDB; AAF5722.		XX
XX	(BIOL) BIOPHON INC.		PA
XX	Worley D;		PI
XX	WPI; 2001-235091/24.		XX
XX	Novel Ret ligand polypeptide useful for suppressing growth of a tumor cell that expresses Ret and for modulating Ret signal transduction involving a cell expressing Ret polypeptide or Ret ligand polypeptide.		XX
PS	Claim 13; Fig 6; 76pp; English.		PS
XX	The invention relates to mouse and human Ret ligand 5 (Ret5) polypeptides. The Ret5 polypeptides can be expressed by standard recombinant methodology. The Ret5 when bound to Ret, acts as a dimerization or autoprophorylation activator. The polypeptides and their antibodies are useful for stimulating growth of or limiting damage to, a tumour cell that expresses Ret, for modulating Ret signal transduction involving a cell expressing the Ret polypeptide. The Ret5 polypeptides, fusion proteins containing the Ret5 and antibodies are useful for stimulating renal tissue growth and/or survival, supporting renal function and minimizing damage to renal tissue after various insults, particularly for treating acute renal failure, acute nephritis, chronic renal failure, nephropic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury and trauma. The compounds are also useful for treating conditions such as neural degeneration where neural growth and regeneration are desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as motor neuron disease, demyelinating disease, bacterial diseases, viral diseases, and prion diseases including Creutzfeldt-Jakob disease. The compounds are also useful for treating disorders due to damage to neural tissue caused by neoplastic impingement, trauma or cerebrovascular events		CC

CC such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the human RetL5 polypeptide

SQ Sequence 282 AA;

Query Match 64.7%; Score 914.5; DB 4; Length 282;
Best Local Similarity 74.6%; Pred. No. 7.4e-77; Matches 173; Conservative 15; Mismatches 41; Indels 3; Gaps 1;

Qy 27 GSASSTEGNCKVEAACTAEDQEQQLRSEYVACQKGRAGRGRGPGSCVSRCCRRLRFP 86
Db 16 GSASSVGNRCVDAEACTADARCORLSEYVACQKIGRA--AQGCPRARCRARRFP 72

Qy 87 ARGPPALTHAILFCGGPACERRQTFAPACASGPOLPSCLPKDRCCRSRRCP 146
Db 73 ARGPPALTHAILFCGGPACERRQTFAPACASGPOLPSCLPKDRCCRSRRCP 132

Qy 147 RLPAFQASCADAPGSRDGCPCBEGPGRCLRAYAGLVLGVNTVNVLYDVSARVAPWGCEAS 206
Db 133 RLLAFQVSCTTAPSADGCLLQDAGCIRAYAGLVLGVNTVNVLYDVSARVAPWGDCGAS 192

Qy 207 GNRERBCEAFKFLTRNPCLGAIQFDSSSPSVLQDQWMPYQNAQKTERA 258
Db 193 GNRERDCEAFKFLTRNPCLGAIQFDSSSPSVLQDQWMPYQNAQKTERA 244

RESULT 12

ABB0218 ID ABB0218 standard; protein; 299 AA.

XX ABB0218;

AC 08-JUL-2002 (first entry)

DE Human putative GPI-anchored isoform b protein SEQ ID NO:5.

XX GFRalpha⁴; glycosyl-phosphatidylinositol; GPI; GDNF; cytosatic; glycosyl-phosphatidyl-inositol-linked GDNF family alpha-receptor; glial cell line derived neurotrophic factor; osteopathic; tumour; neuroprotective; anticonvulsant; neoplasia; endocrine tumour; medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; neuronal disorder; aberrant axonal sprouting.

XX Homo sapiens.

OS Homo sapiens.

PN WO200162795-A1.

DD 30-AUG-2001.

XX 14-NOV-2000; 2000WO-FI000994.

XX 21-FEB-2000; 2000FI-00000394.

XX (LICR-) LICENTIA LTD.

PA Airaksinen M, Saarma M, Poteriaev D, Lindahl M, Timmusk T, Rossi J;

XX DR WPI; 2001-596722/67.

XX N-PSDB; ARIUS1673.

PT New nucleic acid sequence for manufacturing polypeptides for treating endocrine cancers comprises a cDNA encoding a splicing isoform of mammalian growth factor receptor (GFR)alpha4.

XX Claim 9; FIG 22B; 143pp; English.

CC The present invention describes an isolated and purified cDNA sequence encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, osteopathic, neuroprotective and anticonvulsive activities. GFRalpha4 is a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4 polymucleotide sequence can be used for recording GFRalpha4 mediated signalling in neurons or endocrine cells such as thyroid calcitonin producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotide sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for preventing neuronal death or aberrant axonal sprouting. The present sequence represents the human GFRalpha 4 protein, designated putative GPI-anchored isoform b, from the present invention

SQ Sequence 299 AA;

Query Match 54.3%; Score 767.5; DB 4; Length 299;
Best Local Similarity 62.5%; Pred. No. 4.1e-63; Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

Qy 27 GSASSTEGNCKVEAACTAEDQEQQLRSEYVACQKGRAGRGRGPGSCVSRCCRRLRFP 86
Db 16 GSASSVGNRCVDAEACTADARCORLSEYVACQKIGRA--AQGCPRARCRARRFP 72

Qy 87 ARGPPALTHAILFCGGPACERRQTFAPACASGPOLPSCLPKDRCCRSRRCP 146
Db 73 ARGPPALTHAILFCGGPACERRQTFAPACASGPOLPSCLPKDRCCRSRRCP 132

Qy 146 ----- PRLFAFQASCADAPGSRDGCPCBEGPGRCLRAY 177
Db 133 ARAAGPWRGMGRGLSPAHRRPAAOASPFOLSLPLGLVHPSAQPRRLPAGFGRPLPARLRGP 192

Qy 178 AGL-VGTWTPVNLVNDVSARVAPWGCEASGNRREBCEAFKFLTRNPCLGQAQFQSS 236
Db 193 RGVPAGTAVTPVNLVNDVSARVAPWGDCGASGNRREDCEAFKFLTRNPCLGATQAFASG 252

Qy 237 QPSVHQDQMP 247
Db 253 WPPVLDLQMP 263

RESULT 13

ABB0219 ID ABB0219 standard; protein; 182 AA.

XX ABB0219;

AC 08-JUL-2002 (first entry)

DE Human putative soluble isoform c protein SEQ ID NO:6.

XX GFRalpha⁴; glycosyl-phosphatidylinositol; GPI; GDNF; cytosatic; glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor; glial cell line derived neurotrophic factor; osteopathic; tumour; neuroprotective; anticonvulsant; neoplasia; endocrine tumour; medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; neuronal disorder; aberrant axonal sprouting.

XX Homo sapiens.

OS Homo sapiens.

PN WO200162795-A1.

DD 30-AUG-2001.

XX 14-NOV-2000; 2000WO-FI000994.

XX 21-FEB-2000; 2000FI-00000394.

XX (LICR-) LICENTIA LTD.

PA Airaksinen M, Saarma M, Poteriaev D, Lindahl M, Timmusk T, Rossi J;

XX DR WPI; 2001-596722/67.

XX N-PSDB; ARIUS1673.

PT New nucleic acid sequence for manufacturing polypeptides for treating endocrine cancers comprises a cDNA encoding a splicing isoform of mammalian growth factor receptor (GFR)alpha4.

XX Claim 9; FIG 22B; 143pp; English.

CC The present invention describes an isolated and purified cDNA sequence encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, osteopathic, neuroprotective and anticonvulsive activities. GFRalpha4 is a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4 polymucleotide sequence can be used for recording GFRalpha4 mediated signalling in neurons or endocrine cells such as thyroid calcitonin producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotide sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for preventing neuronal death or aberrant axonal sprouting. The present sequence represents the human GFRalpha 4 protein, designated putative GPI-anchored isoform b, from the present invention

DR	WPI; 2001-596722/67.
DR	N-PSDB; ABL51674.
XX	
PT	New nucleic acid sequence for manufacturing polypeptides for treating
PT	endocrine cancers comprises a cDNA encoding a splicing isoform of
PT	mammalian growth factor receptor (GFR)alpha4.
XX	
PS	Claim 9; Fig 23B; 143pp; English.
XX	
CC	The present invention describes an isolated and purified cDNA sequence
CC	encoding a splicing isoform of a mammalian growth factor receptor
CC	osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
CC	a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
CC	neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
CC	polynucleotide sequence can be used for recording GFRalpha4 mediated
CC	signalling in neurons or endocrine cells such as thyroid calcitonin-
CC	producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
CC	cells from the pituitary intermediate lobe. GFRalpha4 protein and
CC	polynucleotide sequences can be used for manufacturing polypeptides
CC	useful for diagnosing and/or treating tumours in parathyroid gland cells,
CC	adrenal chromaffin cells, cells of pituitary intermediate lobe, and
CC	neoplasia, endocrine tumours, medullary thyroid carcinoma and
CC	pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
CC	preventing neuronal death or aberrant axonal sprouting. The present
CC	sequence represents the human GFRalpha 4 protein, designated putative
CC	soluteable isoform C, from the present invention
XX	
SQ	Sequence 182 AA;
Query Match	46.0%; Score 649.5; DB 4; Length 182;
Best Local Similarity	75.8%; Pred. No. 2.3e-52;
Matches	122; Conservative 10; Mismatches 26; Indels 3; Gaps 1;
QY	27 GSASSTEGNRVCEAECTADBDQCOQLRSEVVAQCLGRAGRNGRGPSCVRSRCCRRLRFP 86
Db	16 GSASSVGNRVCDAEACTADBDQCOQLRSEVVAQCLGRAGRNGRGPSCVRSRCCRRLRFP 72
Qy	87 ARGGPPALTHALLFCGCGPACACERRRTPAPACAFSGPQLPPSLKPLDCRSRSRRCP 146
Db	73 ARGPPALTHALLFCPCAGPACACERRRTPVSCAFSGPGLPPSCLPLNFCRSRVRCP 132
Qy	147 RLFARQASCAPAPGSRDGCPERGGPRCIRAVAGLVLGVTVTP 187
Db	133 RLAFQVSTPAPSAPDGLQDQGARCLRAYAGLVLGVSPQAP 173
RESULT 14	
ABB0216	
ID	ABB0216 standard; protein; 190 AA.
AC	ABB0216;
XX	
DT	08-JUL-2002 (first entry)
XX	
DE	Mouse secreted isoform a3/4 protein SEQ ID NO:3.
XX	
KW	GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
KW	glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
KW	glial cell line derived neurotrophic factor; osteopathic; tumour;
KW	neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
KW	medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
KW	neuronal disorder; aberrant axonal sprouting.
XX	
OS	Mus musculus.
PH	Location/Qualifiers
FT	Misc-difference 85 /notes= "encoded by CGC"
FT	Misc-difference 138 /notes= "encoded by TGC"
FT	Misc-difference 139 /notes= "encoded by GTG"
XX	
RESULT 15	
ABB05369	
ID	ABB05369 standard; protein; 132 AA.
XX	
AC	ABB05369;
XX	
DT	12-SEP-2001 (first entry)
XX	

Search completed: January 26, 2005, 13:12:23
Job time : 160 Secs

DE Mouse Gα_i family receptor alpha 4 transmembrane isoform protein.
 XX
 KW Mous; cytostatic; antiinflammatory; immunoregulatory; tissue integrity;
 KW wound healing; immune response; vaccine; cancer; asthma; allergy;
 KW Gα_i family receptor alpha 4 transmembrane isoform; cell trafficking;
 XX therapy; Gfrα4; secreted protein;
 OS Mus sp.
 XX
 PN WO200148192-A1.
 XX
 PD 05-JUL-2001.
 XX
 PP 21-DEC-2000; 2000WO-NZ000256.
 XX
 PR 23-DEC-1999; 99US-0171678P.
 PR 28-NOV-2000; 2000US-00724864.
 XX
 PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX
 PT Watson JD, Murison JG;
 XX
 DR WPI; 2001425665/45.
 XX
 N-PSDB; AAD10139.

Novel isolated polypeptide useful to isolate corresponding interacting proteins or other compounds, to quantitatively determine levels of interacting proteins or other compounds, and as therapeutic target.
 PS
 Claim 6; Page 93; 101pp; English.

XX
 CC The patent discloses novel polynucleotides and their corresponding proteins which play a major role in induction of growth, cell migration and proliferation, cell-cell interaction and the differentiation of tissue-specific cells. These proteins are important in the maintenance of tissue integrity and thus are important in wound healing. They are useful in various assays to determine the biological activity, to raise antibodies, to isolate corresponding interacting proteins or other compounds, to quantitatively determine levels of interacting proteins or other compounds, and as therapeutic target in a whole range of disease states. Compositions comprising the novel proteins of the invention are useful for treating mammalian disorders. Polynucleotides of the invention are useful in genome and physical mapping, in positional cloning of genes, to tag or identify an organism or its reproductive material (as non-disruptive tags for marking organisms), and for the diagnosis and treatment of mammalian diseases which is the consequence of inappropriate expression of kinase genes. They are useful for promoting immune response as part of a vaccine or anti-cancer treatment, as target for cancer treatment, as immunoregulatory and anti-inflammatory molecule, as diagnostic for specific types of cancer and for development of an anti-cancer treatment, and as a target for antagonists in the treatment of diseases such as asthma and allergy. They are also useful to inhibit or enhance the activity of the soluble molecule that binds proteins of the invention, for tissue and neural regeneration, to promote or block cell trafficking, and as anti-inflammatory and/or vaccine adjuvant. The present sequence is mouse Gα_i family receptor alpha 4 (Gfrα4) (Gfrα4)
 CC transmembrane isoform
 XX
 SQ Sequence 132 AA:

Query Match 36.4%; Score 515; DB 4; Length 132;

Best Local Similarity 94.0%; Preq. No. 5.6e-40; Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 145 RPRLFRAQASCAPAGSGSRDGCPEEGSPRCLAYAGLVLGVGTWTPTNVLNDNSARVARPGCE 204
 Db 9 RPRLFRAQASCAPAGSGSRDGCPEEGSPRCLAYAGLVLGVGTWTPTNVLNDNSARVARPGCE 68
 Qy 205 ASGNRREECEAFRKLUFLTRNPOLIDGAIAOFSSQPSVLDQ 244
 Db 69 ASGNRREECEAFRKLUFLTRNPOLIDGAIAOFSSQPSVLDQ 108

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 26, 2005, 13:05:31 ; search time 41 seconds
(without alignments)
605.462 Million cell updates/sec

Title: US-10-019-337E-9
Perfect score: 1413
Sequence: 1 MLSGAYLRLVNLNERPQAVLW.....SVLQDQNNPYQNAGQQAKVEA 258
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR:79,*
1: pir1;*
2: pir2;*
3: pir3;*
4: pir4;*

Pred. No. 19 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	364.5	25.8	397	2 JEB0082	GPI-linked receptor precursor - mouse
2	130.5	9.2	3635	2 T30053	GPI-linked receptor precursor - mouse
3	124.5	8.8	1959	1 AGRT	GPI-linked receptor precursor - mouse
4	124.0	8.8	1574	2 T32954	GPI-linked receptor precursor - mouse
5	123.5	8.7	1964	2 T00059	GPI-linked receptor precursor - mouse
6	122.0	8.6	4006	2 T00070	GPI-linked receptor precursor - mouse
7	118.5	8.4	1797	2 A55677	GPI-linked receptor precursor - mouse
8	116.0	8.2	384	2 S25771	GPI-linked receptor precursor - mouse
9	116.0	8.2	2321	2 S78549	GPI-linked receptor precursor - mouse
10	114.0	8.1	686	2 JC7559	GPI-linked receptor precursor - mouse
11	114.0	8.1	2220	2 A56136	GPI-linked receptor precursor - mouse
12	113.0	8.0	572	2 T29880	GPI-linked receptor precursor - mouse
13	112.5	8.0	1372	2 T5933	GPI-linked receptor precursor - mouse
14	110.5	7.8	476	2 A36478	GPI-linked receptor precursor - mouse
15	110.0	7.8	4135	2 T26269	GPI-linked receptor precursor - mouse
16	109.5	7.7	1798	2 S37869	GPI-linked receptor precursor - mouse
17	108.5	7.7	2318	2 S53306	GPI-linked receptor precursor - mouse
18	108.0	7.6	2018	2 A4105	GPI-linked receptor precursor - mouse
19	107.5	7.6	1203	2 A9175	GPI-linked receptor precursor - mouse
20	107.5	7.6	1955	1 AGCH	GPI-linked receptor precursor - mouse
21	107.5	7.6	2471	2 A43128	GPI-linked receptor precursor - mouse
22	107.0	7.6	2531	2 A43129	GPI-linked receptor precursor - mouse
23	107.0	7.6	3566	1 A40701	GPI-linked receptor precursor - mouse
24	106.5	7.5	335	2 T31560	GPI-linked receptor precursor - mouse
25	105.5	7.5	1184	2 A5184	GPI-linked receptor precursor - mouse
26	105.5	7.5	1801	1 MRTS	GPI-linked receptor precursor - mouse
27	105.5	7.5	2355	2 A40043	GPI-linked receptor precursor - mouse
28	104.5	7.4	2442	2 T29699	GPI-linked receptor precursor - mouse
29	104.5	7.4	335	2 T31561	GPI-linked receptor precursor - mouse

ALIGNMENTS

RESULT 1
JEB0082
GPI-linked receptor precursor - mouse
N: Alternative name: GPralpha-3
C: Species: Mus musculus (house mouse)
C: Date: 21-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C: Accession: JEB0082

R:Nomoto, S ; Ito, S ; Yang, L. X. ; Kiuchi, K. ; Bloch, B. ; Physiol. Rev. Commun. 244, 849-853, 1998
A: Title: Molecular cloning and expression analysis of GPralpha-3, a novel cDNA related to F11-25/Dominant

A: Reference number: JEB0082; PMID:98205811; PMID:9535755
A: Accession: JEB0082
A: Molecule type: mRNA

A: Cross references: UNIPROT:O25118; DBPI:AB008833; NID:92622159; PIDN:BA23562.1; PID:92622159; PIDN:BA23562.1; PID:92622159

C: Comment: This protein plays a distinct role in cell survival and differentiation.

C: Superfamily: Mus musculus GPI-linked receptor

C: Keywords: glycoprotein

F:1-25/Dominant
A: Residues: 1-397 <NON>
A: Cross references: UNIPROT:O25118; DBPI:AB008833; NID:92622159; PIDN:BA23562.1; PID:92622159; PIDN:BA23562.1; PID:92622159

C: Comment: This protein plays a distinct role in cell survival and differentiation.

C: Superfamily: Mus musculus GPI-linked receptor

C: Keywords: glycoprotein

F:1-397/Region: Binding Site: Carbohydrate (Asn) (covalent) #status predicted

Query Match 25.8%; Score 364.5; DB 2; Length 397;

Best Local Similarity 35.1%; Pred. No. 8.4e-23; Matches 86; Conservative 26; Mismatches 102; Indels 31; Gaps 7;

Qy 20 WSLGGCGASASSTEGCNVAAEBCAPDEQCQLRSEYVAQCLGRGWRGSCSRR 79

Db 142 WIQNLSPKLNLKPDSDICLKPLCTUHDKDRLRKYGAECSGI-----RCRHLCL 194

Qy 80 RALRFFPARGPPALTHALFPGC--EGPACMRROTAPACAFSGPQLAPPSCILKFLDR 137

Db 195 AQRSFEKAESHAQCGQCLCPARFDGCCRERRVIAFSCALPS--VTPNCUDRSF 251

Qy 138 CIRSRRCPRLPAFOASCAPR--GSRDGCSEBGRGRCLRAYLAGVLTWTPNLYNSA 195

Db 252 CRADPLCRSLRMLDFOTCPHMIDLTG----CATEQS-RCLRAYGLGLTAMTPNFIISK 307

Qy 196 RVAPWCCEASNRRECEARPKLFTRNPCLDGATQ-----FDSSQSVLQ 242

Db 308 TVALSCTCRGSGNLQDCEQLERSFSQNPCLVATEIAAKMRFHRQLFSQDADSTFVWQQ 367

C:Species: Mus musculus (house mouse)

C: Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 09-Jul-2004

hypothetical prote
probable laminin a
gabi homolog - hum
hypothetical prote
hypothetical prote
hypothetical prote
crumbs protein - f
hypothetical prote
fibropellin 1a - b
notch protein homo
xotch protein - Af
hypothetical prote
fibrillin-2 prec
laminin alpha-1 ch
hypothetical prote
Notch homolog prot

C;Accession: T10053
R;Miner, J.H.; Lewis, R.M.; Sanes, J.R.
submitted to the EMBL Data Library, November 1997
A;Reference number: Z16923
A;Accession: T10053
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-3635 <MIN>
A;Cross-references: UNIPROT:Q61001; EMBL:U37501; NID:g2599231; PID:g2599232
C;Genetics:
A;Gene: Lama5
C;Keywords: basement membrane; cell binding; extracellular matrix
F;1889-1939/Domain: laminin-type EGF-like homology <LEG>
F;1942-1970/Domain: EGF homology <EGF>
Query Match 9.2%; Score 130.5; DB 2; Length 3635;
Best Local Similarity 20.4%; Pred. No. 0.013; Mismatches 97; Indels 135; Gaps 12;
Matches 65; Conservative 21; MisMatched 97; Indels 135; Gaps 12;
QY 24 ORGSASSTE3-----NRCVVAEAC----TADOCOQLRSEVVA-- 59
Db 1763 CARGVYDRTKSLFLGRCPGCCQCHGHSRCLRGSGICVGQNTTEGDOCERCRPGVSSDP 1822
QY 60 -----QCLGRAGNGPGLGSCVRSCTRAIRFFA 87
Db 1823 SNPASPVCPOPLAVPSNNFADGVLRNGRQCLCRPGVAG----ASCRCAFGFG 1876
QY 88 RGPPLPAALHALFGLCGCG-----PACAAERRQTPAPC---ASGPQLA 127
Db 1877 -NPLVIGQSSCOPCDGSGNGDPPNMIFSDCPDPLTGAGRCLLRTGPICERCAFGVGNALL 1935
QY 128 PPSCLK-----PLDRC-----ERSRCCRPLFAPO-----ASCAPAP 159
Db 1936 PGNCCTRDCSCPCTGTCRDPGSGRCCLKAGVITGQRCRCLGQFGEQCQGCRPCACGPAA 1995
QY 160 GSRDGPEEG-----GRCLRAYAGLVGTWVTPNVLNDNSARVARVAPGCGEASGNRR 210
Db 1996 KGSECHPQSGQCHQCQPTGQCLECAPGTYG-----LPEKGRRQCPR 2040
QY 211 ERCEAFLRKLFTRNPCLDG 228
Db 2041 GHCDPHIGHCTCPPGJSG 2058

RESULT 3

AGR1
agrin - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C;Accession: JH0399; A38556
R;RUPP, F., Payan, D.G.; Magill-Solc, C.; Cowan, D.M.; Scheller, R.H.
Neuron 6, 811-823, 1991
A;Title: Structure and expression of a rat agrin.
A;Reference number: JH0399; MUID:1122270; PMID:851019
A;Accession: JH0399
A;Molecule type: mRNA
A;Residues: 1-1779;1799-1959 <RUP>
A;Cross-references: UNIPROT:P25304; GB:M64780; NID:g202798; PIDN:AAA40703.1; PID:g202800
A;Experimental source: embryonic spinal cord
A;Note: it is uncertain whether Met-1, Met-18, or Met-24 is the initiator
R;Rupp, F.; Ozcelik, T.; Limai, M.; Peterson, K.; Francke, U.; Scheller, R.
J. Neurosci. 12, 3535-3544, 1992
A;Title: Structural and chromosomal localization of the mammalian agrin gene.
A;Reference number: A38856; MUID:92407628; PMID:1326608
A;Accession: A38856
A;Molecule type: mRNA
A;Residues: 1-1798 <RUP>
A;Cross-references: GB:S44194
C;Comment: This protein mediates the motor neuron-induced aggregation of acetylcholine receptors.
C;Comment: 90% of rat embryonic transcripts encode the variant labeled below as form 3.
C;Superfamily: agrin; EGF homology; Kazal proteinase inhibitor homology; laminin G repeat
C;Keywords: alternative splicing; duplication; glycoprotein; neuromuscular junction

F;1-1959/Product: agrin, form 1 #status predicted <AG1>
F;1-1777,1799-1959/Product: agrin, form 4 #status predicted <AG4>
F;1-1779,1799-1959/Product: agrin, form 3 #status predicted <AG3>
F;1-1779,1799-1959/Product: agrin, form 5 #status predicted <AG5>
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Accession: T13954
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-1574 <NAK>
A;Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:93449293; PIDN:BAA32462.1; PID:93449293
A;Experimental source: strain Sprague-Dawley; brain

RESULT 4

T13954
MEG6 protein - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C;Accession: T13954
R;Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Saki, N.; Ohara, O.
Genomics 51, 27-34, 1998
A;Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
A;Reference number: Z14126; MUID:98360089; PMID:9633030
A;Accession: T13954
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-1574 <NAK>
A;Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:93449293; PIDN:BAA32462.1; PID:93449293

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 26, 2005, 13:15:47 ; Search time 147 Seconds

(without alignments)
 634.100 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MLLGAYLRLVINTERPQAVW.....SVLQDQWNPYQNAGQAKYEA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1608061 seqs, 361289386 residues

Total number of hits satisfying chosen parameters: 1608061

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0*

Maximum Match 100*

Listing first 45 summaries

Database : Published Applications AA:**

1: /cgm2_6/ptodata/1/pupaa/us07_PUBCOMB.pep:*

2: /cgm2_6/ptodata/1/pupaa/PCT_NEW_PUB.pep:*

3: /cgm2_6/ptodata/1/pupaa/us06_PUBCOMB.pep:*

4: /cgm2_6/ptodata/1/pupaa/us07_PUBCOMB.pep:*

5: /cgm2_6/ptodata/1/pupaa/us07_NEW_PUB.pep:*

6: /cgm2_6/ptodata/1/pupaa/RC7US_PUBCOMB.pep:*

7: /cgm2_6/ptodata/1/pupaa/us08_NEW_PUB.pep:*

8: /cgm2_6/ptodata/1/pupaa/us08_PUBCOMB.pep:*

9: /cgm2_6/ptodata/1/pupaa/us09_PUBCOMB.pep:*

10: /cgm2_6/ptodata/1/pupaa/us09_PUBCOMB.pep:*

11: /cgm2_6/ptodata/1/pupaa/us09_PUBCOMB.pep:*

12: /cgm2_6/ptodata/1/pupaa/us09_NEW_PUB.pep:*

13: /cgm2_6/ptodata/1/pupaa/us10_PUBCOMB.pep:*

14: /cgm2_6/ptodata/1/pupaa/us10_PUBCOMB.pep:*

15: /cgm2_6/prodata/1/pupaa/us10_PUBCOMB.pep:*

16: /cgm2_6/prodata/1/pupaa/us10_PUBCOMB.pep:*

17: /cgm2_6/prodata/1/pupaa/us10_NEW_PUB.pep:*

18: /cgm2_6/prodata/1/pupaa/us11_NEW_PUB.pep:*

19: /cgm2_6/prodata/1/pupaa/us60_NEW_PUB.pep:*

20: /cgm2_6/prodata/1/pupaa/us60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match Length	DB ID	Description
1	515	36.4	132	10	US-09-866-050A-709 Sequence 709, App
2	469	33.2	445	16	US-10-673-007-11 Sequence 11, Appl
3	469	33.2	460	17	US-10-872-161-40 Sequence 40, Appl
4	469	33.2	464	9	US-09-388-316-6 Sequence 6, Appl
5	469	33.2	464	14	US-10-357-822-6 Sequence 6, Appl
6	469	33.2	464	16	US-10-673-007-2 Sequence 2, Appl
7	469	33.2	664	9	US-09-388-316-18 Sequence 18, Appl
8	469	33.2	664	14	US-10-357-822-18 Sequence 18, Appl
9	465	32.9	460	14	US-10-241-220-62 Sequence 62, Appl
10	465	32.9	460	17	US-10-872-972-62 Sequence 62, Appl
11	465	32.9	460	17	US-10-872-991-62 Sequence 10, Appl
12	463	32.9	463	14	US-10-555-633-10 Sequence 12, Appl
13	463	14	US-10-155-693-12		

RESULTS

RESULT 1

US-09-866-050A-709 ; Sequence 709, Application US/09866050A

; Publication No. US20030040471A1

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleman, Matthew

; APPLICANT: Onrus, Rene

; APPLICANT: Murison, James G.

; APPLICANT: Kumble, Krishanand D.

; TITLE OF INVENTION: Compositions Isolated From Skin Cells

; TITLE OF INVENTION: and Methods for Their Use

; FILE REFERENCE: 11000_101c4U

; CURRENT APPLICATION NUMBER: US/09/866,050A

; CURRENT FILING DATE: 2001-05-24

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO: 709

; LENGTH: 132

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

RESULT 2
 US-10-673-007-11
 ; Sequence 11, Application US/10673007
 ; Publication No. US20040126819A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ibanez, Carlos F.
 ; APPLICANT: Arumae, Urmas
 ; APPLICANT: Sarioia, Hannu
 ; APPLICANT: Suvanto, Petri
 ; APPLICANT: Trupp, Miles
 ; APPLICANT: Saarma, Mart
 TITLE OF INVENTION: Gial Cell Line-Derived Neurotropic Factor Receptors
 FILE REFERENCE: CEPH0418
 CURRENT APPLICATION NUMBER: US/10/673,007
 CURRENT FILING DATE: 2003-09-26
 PRIOR APPLICATION NUMBER: US/08/861,990
 PRIOR FILING DATE: 1997-05-22
 PRIOR APPLICATION NUMBER: 08/747,842
 PRIOR FILING DATE: 1996-11-13
 PRIOR APPLICATION NUMBER: 60/006,619
 PRIOR FILING DATE: 1995-11-13
 PRIOR APPLICATION NUMBER: 60/015,767
 PRIOR FILING DATE: 1996-04-16
 PRIOR APPLICATION NUMBER: 60/021,965
 PRIOR FILING DATE: 1996-06-27
 PRIOR APPLICATION NUMBER: 60/020,638
 PRIOR FILING DATE: 1996-06-27
 PRIOR APPLICATION NUMBER: 60/020,639
 PRIOR FILING DATE: 1996-06-27
 NUMBER OF SEQ ID NOS: 11
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 11
 LENGTH: 445
 TYPE: PRT
 ORGANISM: Rattus sp.
 US-10-673-007-11

Query Match 33.2%; Score 469; DB 16; Length 445;
 Best Local Similarity 43.0%; Pred. No. 3.4e-32;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCVAEAACTADEQCQOLRSVVAOCILGRAGWRGPGSCVRSRRAARRFAR 88
 Db 149 AVSTKSNHCLDAAKACNNDCKKLSSVIVSINREIS--PTERCNRKCHKALRQFD 206
 Qy 89 GPPALTHAILFGCGEGPACAPRQTPACASGSPQIAPPSPKLPDRERSRRCPRL 148
 Db 207 VPSEYTYRMFLPCSDQDQCAERRTQLPSCSYEDKE--KPNCLDLRSLCRTDHLCRSRL 264
 Qy 149 FAFOASCAPAGPSRDGCPEEGPRCLRAYLAGLVUTPNYLDN--VSARVAPWCGEAS 206
 Db 265 ADFHFRANCASRYTITSCADNYQACTSSAYGMIGDFMTWVDSNPTGIVVSPWCNGRS 324
 Qy 207 GNRREBECIFRKUFTRNICLGDQAF 233
 Db 325 GNMEEBECEKLFOPTFENPCIRNAIQAF 351

RESULT 3
 US-10-872-161-40
 ; Sequence 40, Application US/10872161
 ; Publication No. US20040235714A1
 ; GENERAL INFORMATION:
 ; APPLICANT: FOX, GARY M.
 ; APPLICANT: JING, SHUQIAN
 ; APPLICANT: WEN, DUANZHI
 TITLE OF INVENTION: GIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
 FILE REFERENCE: A-401D
 CURRENT APPLICATION NUMBER: US/10/872,161
 CURRENT FILING DATE: 2004-06-18
 PRIOR APPLICATION NUMBER: US/08/866,354
 PRIOR FILING DATE: 1997-05-30

RESULT 3
 US-10-872-161-40
 ; Sequence 40, Application US/10872161
 ; Publication No. US20040235714A1
 ; GENERAL INFORMATION:
 ; APPLICANT: FOX, GARY M.
 ; APPLICANT: JING, SHUQIAN
 ; APPLICANT: WEN, DUANZHI
 TITLE OF INVENTION: GIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
 FILE REFERENCE: A-401D
 CURRENT APPLICATION NUMBER: US/10/872,161
 CURRENT FILING DATE: 2004-06-18
 PRIOR APPLICATION NUMBER: US/08/866,354
 PRIOR FILING DATE: 1997-05-30

RESULT 4
 US-09-388-316-6
 ; Sequence 6, Application US/09388316
 ; Publication No. US20020051972A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
 TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSER: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94180
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatin (Genentech)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/388,316
 FILING DATE: 01-Sep-1999
 CLASSIFICATION: <Unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 09/024, 665
 FILING DATE: <Unknown>
 APPLICATION NUMBER: 60/049818
 FILING DATE: 9-Jun-1997
 APPLICATION NUMBER: 60/038839
 FILING DATE: 18-Feb-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD., Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086R3
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 464 amino acids

TYPE: Amino Acid

TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 6:

US-09-388-316-6

Query Match 33.2%; Score 469; DB 9; Length 464;
Best Local Similarity 43.0%; Pred. No. 3.5e-32; Gaps 3;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSTEGNRVCEAACTADEQCQQLRSEYVAQCLGRAGRGGPGSCRSRRALRFFAR 88

Db 153 AVSTKSNHCLDAAKCNLNDCKKLRSYISICREIS--PTERCRNKKHKAQFDFR 210

QY 89 GPPALTHALLFCGCGPACRERRTAPACAFSGPQLPSPCKPLDRCRSRCPRL 148

Db 211 VPSEVYTMILFCSCDQACRERRTILPSCSYEDKE--KNCIDLRSCLRTDHLCRSRL 268

QY 207 GAFQSCAPGSRGDCPSEGPGPCLRAYAGLUVTWPNLDN--VSARVAPGCCAS 206

Db 269 ADFHANCASRYTITSCPADNYQACIGSYAGMIGFDMTTPNYVDSPNPTGIWVSPWCRCGS 328

Db 329 GMMEBECEKFRLDFTENPCRNIAQF 355

RESULT 5

US-10-357-822-6
; Sequence 6, Application US/10357822
; Publication No. US20030110525A1

GENERAL INFORMATION:

APPLICANT: KLEIN, ROBERT D.

APPLICANT: ROSENTHAL, ARNON

APPLICANT: HYNES, MARY A.

TITLE OF INVENTION: NEURTURIN RECEPTOR

FILE REFERENCE: CEPHO418

CURRENT APPLICATION NUMBER: US/10/673, 007

PRIOR APPLICATION NUMBER: US/08/861, 990

PRIOR FILING DATE: 1997-05-22

PRIOR APPLICATION NUMBER: 08/747, 842

PRIOR FILING DATE: 1996-11-13

PRIOR APPLICATION NUMBER: 6/006, 619

PRIOR FILING DATE: 1995-11-13

PRIOR APPLICATION NUMBER: 6/015, 767

PRIOR FILING DATE: 1995-04-16

PRIOR APPLICATION NUMBER: 6/021, 965

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 638

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 639

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 640

PRIOR APPLICATION NUMBER: 6/020, 641

PRIOR APPLICATION NUMBER: 6/020, 642

PRIOR APPLICATION NUMBER: 6/020, 643

PRIOR APPLICATION NUMBER: 6/020, 644

PRIOR APPLICATION NUMBER: 6/020, 645

PRIOR APPLICATION NUMBER: 6/020, 646

US-10-357-822-6

; Sequence 6, Application US/10357822
; Publication No. US20030110525A1

GENERAL INFORMATION:

APPLICANT: Ibanez, Carlos F.

APPLICANT: Arumae, Urmas

APPLICANT: Sariola, Hannu

APPLICANT: Suvento, Petro

APPLICANT: Trapp, Miles

APPLICANT: Saarma, Mart

TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptor

FILE REFERENCE: CEPHO418

CURRENT APPLICATION NUMBER: US/10/673, 007

PRIOR APPLICATION NUMBER: US/08/861, 990

PRIOR FILING DATE: 1997-05-22

PRIOR APPLICATION NUMBER: 08/747, 842

PRIOR FILING DATE: 1996-11-13

PRIOR APPLICATION NUMBER: 6/006, 619

PRIOR FILING DATE: 1995-11-13

PRIOR APPLICATION NUMBER: 6/015, 767

PRIOR FILING DATE: 1995-04-16

PRIOR APPLICATION NUMBER: 6/021, 965

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 638

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 639

US-10-673-007-2

Query Match 33.2%; Score 469; DB 16; Length 464;

Best Local Similarity 43.0%; Pred. No. 3.5e-32; Gaps 3;

Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSTEGNRVCEAACTADEQCQQLRSEYVAQCLGRAGRGGPGSCRSRRALRFFAR 88

Db 153 AVSTKSNHCLDAAKCNLNDCKKLRSYISICREIS--PTERCRNKKHKAQFDFR 210

QY 89 GPPALTHALLFCGCGPACRERRTAPACAFSGPQLPSPCKPLDRCRSRCPRL 148

Db 211 VPSEVYTMILFCSCDQACRERRTILPSCSYEDKE--KNCIDLRSCLRTDHLCRSRL 268

QY 207 GAFQSCAPGSRGDCPSEGPGPCLRAYAGLUVTWPNLDN--VSARVAPGCCAS 206

Db 269 ADFHANCASRYTITSCPADNYQACIGSYAGMIGFDMTTPNYVDSPNPTGIWVSPWCRCGS 328

Db 329 GMMEBECEKFRLDFTENPCRNIAQF 355

RESULT 6

US-10-673-007-2
; Sequence 2, Application US/10673007
; Publication No. US20040126819A1

GENERAL INFORMATION:

APPLICANT: Klein, Carlos F.

APPLICANT: Arumae, Urmas

APPLICANT: Sariola, Hannu

APPLICANT: Suvento, Petro

APPLICANT: Trapp, Miles

APPLICANT: Saarma, Mart

TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptor

FILE REFERENCE: CEPHO418

CURRENT APPLICATION NUMBER: US/10/673, 007

PRIOR APPLICATION NUMBER: 08/747, 842

PRIOR FILING DATE: 1996-11-13

PRIOR APPLICATION NUMBER: 6/006, 619

PRIOR FILING DATE: 1995-11-13

PRIOR APPLICATION NUMBER: 6/015, 767

PRIOR FILING DATE: 1995-04-16

PRIOR APPLICATION NUMBER: 6/021, 965

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 638

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 639

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 640

PRIOR APPLICATION NUMBER: 6/020, 641

PRIOR APPLICATION NUMBER: 6/020, 642

PRIOR APPLICATION NUMBER: 6/020, 643

PRIOR APPLICATION NUMBER: 6/020, 644

PRIOR APPLICATION NUMBER: 6/020, 645

PRIOR APPLICATION NUMBER: 6/020, 646

RESULT 7

US-09-388-316-18
; Sequence 18, Application US/09188316

GENERAL INFORMATION:

APPLICANT: Klein, Robert D.

APPLICANT: Arumae, Urmas

APPLICANT: Sariola, Hannu

APPLICANT: Suvento, Petro

APPLICANT: Trapp, Miles

APPLICANT: Saarma, Mart

TITLE OF INVENTION: Neurturin Receptor

FILE REFERENCE: CEPHO418

CURRENT APPLICATION NUMBER: US/10/673, 007

PRIOR APPLICATION NUMBER: 08/747, 842

PRIOR FILING DATE: 1996-11-13

PRIOR APPLICATION NUMBER: 6/006, 619

PRIOR FILING DATE: 1995-11-13

PRIOR APPLICATION NUMBER: 6/015, 767

PRIOR FILING DATE: 1995-04-16

PRIOR APPLICATION NUMBER: 6/021, 965

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 638

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 639

PRIOR FILING DATE: 1996-06-27

PRIOR APPLICATION NUMBER: 6/020, 640

PRIOR APPLICATION NUMBER: 6/020, 641

PRIOR APPLICATION NUMBER: 6/020, 642

PRIOR APPLICATION NUMBER: 6/020, 643

PRIOR APPLICATION NUMBER: 6/020, 644

PRIOR APPLICATION NUMBER: 6/020, 645

PRIOR APPLICATION NUMBER: 6/020, 646

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Winratin (Genentech)

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/388,316
 FILING DATE: 01-Sep-1999
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 09/024,665
 FILING DATE: <Unknown>
 APPLICATION NUMBER: 60/049818
 FILING DATE: 9-Jun-1997
 APPLICATION NUMBER: 60/038839
 FILING DATE: 18-Feb-1997

ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD, Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086R3

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/7225-8674
 TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 18:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 664 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 18:
 US-09-388-316-18

Query Match 33.2%; Score 469; DB 9; Length 664;
 Best Local Similarity 43.0%; Pred. No. 5.2e-32; Mismatches 79; Indels 6; Gaps 3;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSPREGNCVVEAACTADEQOCQLRSEYVAQCLGRAGWRGGSCVSRCCRRLRRPAR 88
 153 AVSTKSNHCLDAAKACNLDNCKKLRSYISCNREIS--PTERCRNRKCHKALRQFFDR 210

QY 89 GPPALTHALLFCGEGPACERRQTAPACAFSGPQLAPPSCIKPLDRERSRRCPRL 148
 211 VPSEVTYRMLFSCQDODAACERRQTIPSCSYEDKE--KPNGLDLRSLCRLDHLCSRL 268

QY 149 FAFOASCPAPGSRDGCPEEGPRCLRAYAGLVGTWTPNYLDN--VSARVAPWCGEAS 206
 Db 269 ADFHANCRASTRYTITSCPADNYQACLGSSYAGMIGFDMPNTPYDSNPIGIVVSPWCNRGS 328

QY 207 GNRBECCEAFRKLTFRNCPCDGAQAF 233
 Db 329 GNMEECEKFLRDPFTENBCLRNAIQAF 355

RESULT 8
 US-10-357-822-18

Sequence 18 Application US/10357822
 Publication No. US20030110525A1

GENERAL INFORMATION:

APPLICANT: KLEIN, ROBERT D.

APPLICANT: ROSENTHAL, ARNON

APPLICANT: HYNES, MARY A.

TITLE OF INVENTION: NEURTURIN RECEPTOR

FILE REFERENCE: GENET-45A2D1

CURRENT APPLICATION NUMBER: US/10/357,822

PRIOR APPLICATION NUMBER: US/09/388,316C

PRIOR FILING DATE: 1999-09-01

Query Match 32.9%; Score 465; DB 14; Length 460;
 Best Local Similarity 41.9%; Pred. No. 7.8e-32; Mismatches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVVEAACTADEQOCQLRSEYVAQCLGRAGWRGGSCVSRCCRRLRFARGPPA 92
 Db 145 KGNCICDAKACNLDDICKRSAYITPCITSV--SNDVCRNRKCHKALRQFPDKVPP 201

RESULT 9
 US-10-241-220-62

Sequence 62, Application US/10241220
 Publication No. US20030148408A1

GENERAL INFORMATION:

APPLICANT: Frantz, Gretchen

APPLICANT: Hillian, Kenneth J.

APPLICANT: Phillips, Heidi

APPLICANT: Polakis, Paul

APPLICANT: Spencer, Susan

APPLICANT: Williams, P. Mickey

APPLICANT: Wu, Thomas

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
 TREATMENT OF TUMOR

FILE REFERENCE: P3010R-US

CURRENT APPLICATION NUMBER: US/10/241,220

CURRENT FILING DATE: 2002-12-13

NUMBER OF SEQ ID NOS: 120

SEQ ID NO 62
 LENGTH: 460
 TYPE: PRT
 ORGANISM: Homo Sapien

US-10-241-220-62

Query Match 32.9%; Score 465; DB 14; Length 460;
 Best Local Similarity 41.9%; Pred. No. 7.8e-32; Mismatches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 93 LTHALIFGCCGEGACERRRTPAPACFSGPQLAPSPCLKFLDRCRERSRCRPRLEAQ 152 ; APPLICANT: Zhang/Zemin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; PUBLICATION NO. US20040229277A1 ; FILE REFERENCE: F5010RI-US
; GENERAL INFORMATION: CURRENT APPLICATION NUMBER: US/10/872,991 ; CURRENT FILING DATE: 2004-05-21
; APPLICANT: Frantz,Gretchen ; PRIORITY NUMBER: US/10/241,220
; APPLICANT: Hillian,Kenneth J. ; PRIORITY FILING DATE: 2002-09-11
; APPLICANT: Phillips,Heidi ; NUMBER OF SEQ ID NOS: 120
; APPLICANT: Polakis,Paul ; SEQ ID NO: 62
; APPLICANT: Spencer,Susan ; LENGTH: 460
; APPLICANT: Williams,P.Mickey ; TYPE: PRT
; APPLICANT: Wu,Thomas ; ORGANISM: Homo Sapien
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; PUBLICATION NO. US20040229277A1 ; FILE REFERENCE: F5010RI-US
; TITLE OF INVENTION: TREATMENT OF TUMOR ; CURRENT APPLICATION NUMBER: US/10/872,972
; FILE REFERENCE: P5010RI-US ; CURRENT FILING DATE: 2004-06-21
; PRIORITY NUMBER: US/10/241,220 ; PRIORITY FILING DATE: 2002-09-11
; NUMBER OF SEQ ID NOS: 120 ; SEQ ID NO: 62
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Homo Sapien

RESULT 10 ; US-10-872-972-62
; Sequence 62, Application US/10872972
; Publication No. US20040229277A1
; GENERAL INFORMATION:
; APPLICANT: Frantz,Gretchen
; APPLICANT: Hillian,Kenneth J.
; APPLICANT: Phillips,Heidi
; APPLICANT: Polakis,Paul
; APPLICANT: Spencer,Susan
; APPLICANT: Williams,P.Mickey
; APPLICANT: Wu,Thomas
; APPLICANT: Zhang,Zemin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; PUBLICATION NO. US20040229277A1 ; FILE REFERENCE: F5010RI-US
; TITLE OF INVENTION: TREATMENT OF TUMOR ; CURRENT APPLICATION NUMBER: US/10/872,991 ; CURRENT FILING DATE: 2004-05-21
; PRIORITY NUMBER: US/10/241,220 ; PRIORITY FILING DATE: 2002-09-11
; NUMBER OF SEQ ID NOS: 120 ; SEQ ID NO: 62
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Homo Sapien

US-10-872-991-62
; Sequence 62, Application US/10872972
; Publication No. US20040229277A1
; GENERAL INFORMATION:
; APPLICANT: Frantz,Gretchen
; APPLICANT: Hillian,Kenneth J.
; APPLICANT: Phillips,Heidi
; APPLICANT: Polakis,Paul
; APPLICANT: Spencer,Susan
; APPLICANT: Williams,P.Mickey
; APPLICANT: Wu,Thomas
; APPLICANT: Zhang,Zemin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; PUBLICATION NO. US20040229277A1 ; FILE REFERENCE: F5010RI-US
; TITLE OF INVENTION: TREATMENT OF TUMOR ; CURRENT APPLICATION NUMBER: US/10/872,991 ; CURRENT FILING DATE: 2004-05-21
; PRIORITY NUMBER: US/10/241,220 ; PRIORITY FILING DATE: 2002-09-11
; NUMBER OF SEQ ID NOS: 120 ; SEQ ID NO: 62
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Homo Sapien

RESULT 11 ; US-10-872-991-62
; Sequence 62, Application US/10872991
; Publication No. US20040229277A1
; GENERAL INFORMATION:
; APPLICANT: Frantz,Gretchen
; APPLICANT: Hillian,Kenneth J.
; APPLICANT: Phillips,Heidi
; APPLICANT: Polakis,Paul
; APPLICANT: Spencer,Susan
; APPLICANT: Williams,P.Mickey

RESULT 12 ; US-10-155-693-10
; Sequence 10, Application US/10155693
; Publication No. US20030175876A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUQIAN
; APPLICANT: WEN, DUANZHI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; PUBLICATION NO. US20030175876A1 ; FILE REFERENCE: A-401C
; CURRENT APPLICATION NUMBER: US/10/155,693 ; CURRENT FILING DATE: 2002-05-24
; PRIORITY NUMBER: US/08/837,199 ; PRIORITY FILING DATE: 1997-04-14
; PRIORITY NUMBER: US 60/015,907 ; PRIORITY FILING DATE: 1996-04-22
; PRIORITY NUMBER: US 60/017,221 ; PRIORITY FILING DATE: 1996-05-09
; NUMBER OF SEQ ID NOS: 47 ; SOFTWARE: Patentin version 3.1
; SEQ ID NO: 10 ; LENGTH: 463
; TYPE: PRT
; ORGANISM: HUMAN
; FEATURES:
; NAME/KEY: misc_feature
; LOCATION: (5)-(5) ; OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
; GENERAL INFORMATION:
; NAME/KEY: misc_feature
; LOCATION: (1)-(537) ; OTHER INFORMATION: No. US20030175876A1= "1 to 537 is -235 to 301 of Figure 5 liaison
; FEATURES:
; NAME/KEY: misc_feature
; LOCATION: (550)-(550) ; OTHER INFORMATION: N in position 550 indicates any nucleic acid

US-10-155-693-10

Query Match 32.9%; Score 465; DB 14; Length 463; US-10-872-161-10

Best Local Similarity 41.9%; Pred. No. 7.8e-32; Publication No. US10872161

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3; Publication No. US20040235714A1

GENERAL INFORMATION:

APPLICANT: FOX, GARY M.

APPLICANT: JING, SHUQIAN

APPLICANT: WEN, DUANZHI

TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR

FILE REFERENCE: A-401D

CURRENT APPLICATION NUMBER: US/10/872,161

CURRENT FILING DATE: 2004-06-18

PRIOR APPLICATION NUMBER: US/08/866,354

PRIOR FILING DATE: 1997-05-30

PRIOR APPLICATION NUMBER: US 60/015,907

PRIOR FILING DATE: 1996-04-22

PRIOR APPLICATION NUMBER: US 60/017,221

PRIOR FILING DATE: 1996-05-09

PRIOR APPLICATION NUMBER: US 08/837,199

PRIOR FILING DATE: 1997-04-14

NUMBER OF SEQ ID NOS: 61

SOFTWARE: PatentIn version 3.2

SEQ ID NO 10

LENGTH: 463

TYPE: PRT

ORGANISM: HUMAN

FEATURE:

NAME/KEY: misc_feature

LOCATION: (5). (5)

OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.

US-10-872-161-10

Query Match 32.9%; Score 465; DB 17; Length 463; US-10-872-161-10

Best Local Similarity 41.9%; Pred. No. 7.8e-32; Publication No. US10872161

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3; Publication No. US20040235714A1

GENERAL INFORMATION:

APPLICANT: FOX, GARY M.

APPLICANT: JING, SHUQIAN

APPLICANT: WEN, DUANZHI

TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR

FILE REFERENCE: A-401C

CURRENT APPLICATION NUMBER: US/10/872,161

CURRENT FILING DATE: 2004-06-18

PRIOR APPLICATION NUMBER: US/08/866,354

PRIOR FILING DATE: 1997-05-30

PRIOR APPLICATION NUMBER: US 60/015,907

PRIOR FILING DATE: 1996-04-22

PRIOR APPLICATION NUMBER: US 60/017,221

PRIOR FILING DATE: 1996-05-09

PRIOR APPLICATION NUMBER: US 08/837,199

PRIOR FILING DATE: 1997-04-14

NUMBER OF SEQ ID NOS: 61

SOFTWARE: PatentIn version 3.1

SEQ ID NO 12

LENGTH: 463

TYPE: PRT

ORGANISM: HUMAN

FEATURE:

NAME/KEY: misc_feature

LOCATION: (5). (5)

OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.

US-10-872-161-10

Query Match 32.9%; Score 465; DB 17; Length 463; US-10-872-161-10

Best Local Similarity 41.9%; Pred. No. 7.8e-32; Publication No. US10872161

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3; Publication No. US20040235714A1

GENERAL INFORMATION:

APPLICANT: FOX, GARY M.

APPLICANT: JING, SHUQIAN

APPLICANT: WEN, DUANZHI

TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR

FILE REFERENCE: A-401D

CURRENT APPLICATION NUMBER: US/10/872,161

CURRENT FILING DATE: 2004-06-18

PRIOR APPLICATION NUMBER: US/08/866,354

PRIOR FILING DATE: 1997-05-30

PRIOR APPLICATION NUMBER: US 60/015,907

PRIOR FILING DATE: 1996-04-22

PRIOR APPLICATION NUMBER: US 60/017,221

PRIOR FILING DATE: 1996-05-09

PRIOR APPLICATION NUMBER: US 08/837,199

PRIOR FILING DATE: 1997-04-14

NUMBER OF SEQ ID NOS: 61

SOFTWARE: PatentIn version 3.2

SEQ ID NO 10

LENGTH: 463

TYPE: PRT

ORGANISM: HUMAN

FEATURE:

NAME/KEY: misc_feature

LOCATION: (5). (5)

OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.

US-10-872-161-10

Query Match 32.9%; Score 465; DB 17; Length 463; US-10-872-161-10

Best Local Similarity 41.9%; Pred. No. 7.8e-32; Publication No. US10872161

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3; Publication No. US20040235714A1

GENERAL INFORMATION:

APPLICANT: FOX, GARY M.

APPLICANT: JING, SHUQIAN

APPLICANT: WEN, DUANZHI

TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR

FILE REFERENCE: A-401C

CURRENT APPLICATION NUMBER: US/10/872,161

CURRENT FILING DATE: 2004-06-18

PRIOR APPLICATION NUMBER: US/08/866,354

PRIOR FILING DATE: 1997-05-30

PRIOR APPLICATION NUMBER: US 60/015,907

PRIOR FILING DATE: 1996-04-22

PRIOR APPLICATION NUMBER: US 60/017,221

PRIOR FILING DATE: 1996-05-09

; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 1
; LENGTH: 463
; TYPE: PRT
; ORGANISM: HUMAN
US-10-872-161-12

Query Match 32.9%; Score 465; DB 17; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;
Oy 33 EGSRCVVEAEEACTADEQCOQLSSEBYAOCGLRGAGWRGPSCYVSRCCRRLRREFARGPPA 92
Db 150 KGNCLDPAKACWLDICKKYSAYITCTSV--SNDVCNRKCKALRQFDKYPAK 206
Oy 93 LTHALLFCGCEGPGACASERRQTAPACAFSGPQLAPPSCLPKUDCRCSRERPRLPAFO 152
Db 207 HSTGMILFCSRDIACTERRRQTIVPVESYE--BREKENCNLQDSCKNYICRSRLADPF 264
Oy 153 ASCAPAPCPSRRGCPEEGPRCURAYAGIVGTUTPNYLNVNSARAVAMCGCEASGRRE 212
Db 265 TNQOPESRSVSSCLKENYADCLILAYSLIGTWTNPYIDSSLSVABWCDCNSGNDLEE 324
Oy 213 CEAFLKLFTRNPCLDGAQAFDSSQPSVLQDQNP 247
Db 325 CLKFLNFFKDNTCLKNAIQAFNGSDVTv--WQP 356

Search completed: January 26, 2005, 13:28:26
Job time : 149 sec

